<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Novel Dopamine Therapeutics for Cognitive Deficits in Schizophrenia</title>
				<funder ref="#_F52nPST #_TnKf77r #_f4JqDcj">
					<orgName type="full">unknown</orgName>
				</funder>
				<funder ref="#_vbDgNGe">
					<orgName type="full">PHS</orgName>
				</funder>
			</titleStmt>
			<publicationStmt>
				<publisher>Elsevier BV</publisher>
				<availability status="unknown"><p>Copyright Elsevier BV</p>
				</availability>
				<date type="published" when="2018-01-01">2018 January 01.</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><roleName>Dr</roleName><forename type="first">Amy</forename><forename type="middle">F T</forename><surname>Arnsten</surname></persName>
							<email>amy.arnsten@yale.edu</email>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Neurobiology</orgName>
								<orgName type="department" key="dep2">Yale Medical School</orgName>
								<address>
									<postCode>06510</postCode>
									<settlement>New Haven</settlement>
									<region>CT</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ragy</forename><forename type="middle">R</forename><surname>Girgis</surname></persName>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Department of Psychiatry</orgName>
								<orgName type="department" key="dep2">College of Physicians and Surgeons</orgName>
								<orgName type="institution">Columbia University</orgName>
								<address>
									<postCode>10032</postCode>
									<settlement>New York</settlement>
									<region>NY</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">David</forename><forename type="middle">L</forename><surname>Gray</surname></persName>
							<email>david.l.gray@pfizer.com</email>
							<affiliation key="aff2">
								<orgName type="institution" key="instit1">Neuroscience &amp; Pain Research Unit</orgName>
								<orgName type="institution" key="instit2">Pfizer Worldwide Research and Development</orgName>
								<address>
									<postCode>02139</postCode>
									<settlement>Cambridge</settlement>
									<region>MA</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Richard</forename><forename type="middle">B</forename><surname>Mailman</surname></persName>
							<email>rmailman@psu.edu</email>
							<affiliation key="aff3">
								<orgName type="department">Department of Pharmacology</orgName>
								<orgName type="institution">Pennsylvania State University College of Medicine</orgName>
								<address>
									<postCode>17036</postCode>
									<settlement>Hershey</settlement>
									<region>PA</region>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff4">
								<orgName type="department">Yale Medical School</orgName>
								<address>
									<addrLine>333 Cedar St</addrLine>
									<postCode>06510</postCode>
									<settlement>New Haven</settlement>
									<region>CT</region>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Novel Dopamine Therapeutics for Cognitive Deficits in Schizophrenia</title>
					</analytic>
					<monogr>
						<title level="j" type="main">Biological Psychiatry</title>
						<title level="j" type="abbrev">Biological Psychiatry</title>
						<idno type="ISSN">0006-3223</idno>
						<imprint>
							<publisher>Elsevier BV</publisher>
							<biblScope unit="volume">81</biblScope>
							<biblScope unit="issue">1</biblScope>
							<biblScope unit="page" from="67" to="77"/>
							<date type="published" when="2018-01-01">2018 January 01.</date>
						</imprint>
					</monogr>
					<idno type="MD5">974CFF67B8F0C291E9E826462BCBB967</idno>
					<idno type="DOI">10.1016/j.biopsych.2015.12.028</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.8.0" ident="GROBID" when="2025-04-21T20:08+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>prefrontal cortex</term>
					<term>D1 agonist</term>
					<term>working memory</term>
					<term>schizophrenia</term>
					<term>executive function</term>
					<term>D2 receptors</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Schizophrenia is characterized by profound cognitive deficits that are not alleviated by currently available medications.</s><s>Many of these cognitive deficits involve dysfunction of the newly evolved, dorsolateral prefrontal cortex (dlPFC).</s><s>The brains of patients with schizophrenia show evidence of dlPFC pyramidal cell dendritic atrophy, likely reductions in cortical dopamine (DA), and possible changes in DA D 1 receptors (D 1 R).</s><s>It has been appreciated for decades that optimal levels of DA are essential for dlPFC working memory function, with many beneficial actions arising from D 1 R stimulation.</s><s>D 1 R are concentrated on dendritic spines in the primate dlPFC, where their stimulation produces an inverted U dose-response on dlPFC neuronal firing and cognitive performance during working memory tasks.</s><s>Research in both academia and the pharmaceutical industry has led to the development of selective D 1 agonists, e.g., the first full D 1 agonist, dihydrexidine, which at low doses improved working memory in monkeys.</s><s>Dihydrexidine has begun to be tested in patients with schizophrenia or schizotypal disorder.</s><s>Initial results are encouraging, but studies are limited by the pharmacokinetics of the drug.</s><s>These data have, however, spurred efforts towards the discovery and development of improved or novel new compounds, including D 1 agonists with better pharmacokinetics, functionally selective D 1 ligands, and D 1 R positive allosteric modulators.</s><s>One or several of these approaches should allow</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>General Introduction</head><p><s>Drugs targeting dopamine (DA) receptors have been a cornerstone of schizophrenia pharmacotherapy for more than a half-century.</s><s>To date, all approved antipsychotic drugs target DA D 2 receptors (D 2 R), and although these agents can reduce positive symptoms, improvement of cognitive function, if any, is modest and difficult to dissociate from other drug effects <ref type="bibr" target="#b0">(1,</ref><ref type="bibr" target="#b1">2)</ref>.</s><s>Schizophrenia involves profound dysfunction of the newly evolved, dorsolateral prefrontal cortex (dlPFC).</s><s>The pioneering research of Patricia Goldman-Rakic uncovered the neuronal circuits in dlPFC that generate the mental representations needed for working memory that are the foundation of abstract thought.</s><s>She discovered that the dlPFC is greatly influenced by DA, as DA depletion causes profound impairment in working memory <ref type="bibr" target="#b2">(3)</ref>.</s><s>Thus, enhancing DA's beneficial actions is a logical approach to ameliorating cognitive deficits.</s></p><p><s>Five DA receptor genes encode six receptors in humans (D 1 , D 2L , D 2S , D 3 , D 4 , D 5 ).</s><s>Two of these, the D 1 and D 5, are very homologous such that no current drugs are adequately selective for them.</s><s>Because of this, when we refer to D 1 agonists or antagonists we mean compounds that bind to both D 1 and D 5 receptors.</s><s>The members of the D 2 -like family include the D 2L and D 2S (splice variants), D 3 , and D 4 receptors.</s><s>Although there are some selective ligands for these subtypes, except where noted, our references to D 2 drugs will indicate compounds with modest or no selectivity among D 2L , D 2S , D 3 or D 4 receptors.</s><s>We shall focus on the rationale for DA therapeutics as cognitive-enhancers, specifically the role of the D 1 receptor (D 1 R).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Dopamine influences on the dlPFC microcircuits afflicted in schizophrenia</head><p><s>Schizophrenia is characterized by striking deficits in cognitive function, especially the higher cognitive operations that depend on the dlPFC.</s><s>In contrast to rodents, DA axons project throughout most of the primate cortex, with greatest innervation of the motor cortices and least in the primary visual cortex.</s><s>The DA neurons that project to the dlPFC are likely "salience" cells that fire in response to both rewarding and aversive events, e.g. during stress exposure.</s><s>Analyses of post-mortem brain tissue have identified grave insults to the layer III microcircuits that subserve working memory, including spine loss and underactivity of layer III pyramidal cells <ref type="bibr" target="#b3">(4)</ref>.</s><s>In monkeys, these pyramidal cells generate the persistent firing needed for working memory, whereas GABAergic interneurons refine the tuning of the circuits.</s><s>Together, they generate the mental representations, the foundation of abstract thought, that keep information "in mind" in the absence of sensory stimulation.</s><s>These neurons are termed "Delay cells," and their activity is greatly influenced by D 1 R, but not D 2 R stimulation.</s></p><p><s>Thus, studies of the actions of DA receptors in the primate dlPFC (reviewed in 5) have shown that optimal levels of D 1 R stimulation are essential for working memory function.</s><s>Layer III pyramidal cells excite each other through NMDA receptor (NMDAR) synapses on spines; NMDAR channel opening depends on cholinergic stimulation of nicotinic α 7 receptors (α 7 nChR) within the glutamate synapse <ref type="bibr" target="#b5">(6)</ref>.</s><s>Defects in both NMDAR and α 7 nChR have been linked to schizophrenia.</s><s>D 1 Rs are concentrated on layer III spines, and can even be found within the synapse (Figure <ref type="figure" target="#fig_0">1A</ref>).</s><s>D 1 Rs are often co-localized with HCN (Hyperpolarization-activated cyclic nucleotide gated) channels on spines; D 1 R mediated increases in cAMP open HCN channels and reduce synaptic efficacy (Figure <ref type="figure" target="#fig_0">1A</ref>).</s><s>The effects of D 1 R stimulation on Delay cell firing are schematically summarized in Figure <ref type="figure" target="#fig_0">1B</ref>.</s><s>Evidence suggests that low levels of D 1 R stimulation increase firing by maintaining NMDAR within the synapse, whereas slightly greater D 1 R activity sculpts away "noise" by gating out non-preferred inputs via HCN channel opening <ref type="bibr" target="#b6">(7)</ref>.</s><s>Conversely, high levels of stimulation (e.g., as occur during stress) suppress all firing.</s><s>This results in an inverted U dose response to D 1 agonists seen at the behavioral level.</s><s>As described below, there is evidence of reduced DA levels in the dlPFC in schizophrenia, and thus therapeutic strategies have focused on enhancing D 1 R stimulation.</s><s>Of particular relevance to treatment development for schizophrenia, Castner et al. <ref type="bibr" target="#b7">(8)</ref> found that intermittent, trace doses (0.00001-0.0001</s><s>mg/kg) of a D 1 agonist could ameliorate working memory deficits induced in monkeys by haloperidol, effects possibly due to indirect down-regulation of D 1 receptors caused by haloperidol.</s><s>These data spurred efforts to determine if low levels of D 1 R stimulation could improve cognitive function in patients.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Approaches to modulating dopamine function D 1 antagonists</head><p><s>As the understanding of D 1 R microcircuitry was evolving, and the first selective antagonist SCH23390 (Figure <ref type="figure" target="#fig_1">2</ref>) was reported <ref type="bibr" target="#b8">(9)</ref>, one prevalent hypothesis was that D 1 R antagonists might be novel treatments for schizophrenia <ref type="bibr" target="#b9">(10)</ref>.</s><s>SCH-23390 has pharmacokinetic limitations, but its analog SCH39166 (ecopipam, Figure <ref type="figure" target="#fig_1">2</ref>) had improved properties <ref type="bibr" target="#b10">(11)</ref>.</s><s>Ecopipam was studied clinically for a variety of indications, including schizophrenia <ref type="bibr" target="#b11">(12)</ref><ref type="bibr" target="#b12">(13)</ref><ref type="bibr" target="#b13">(14)</ref><ref type="bibr" target="#b14">(15)</ref>, drug abuse <ref type="bibr" target="#b15">(16)</ref>, and obesity <ref type="bibr" target="#b16">(17)</ref>, but in each case undesirable effects were observed.</s><s>In addition to the basic neurobiology discussed above, it was "back-translation" of the observations with D 1 R antagonists [e.g., induction of preclinical amotivational states and cognitive deficits <ref type="bibr" target="#b17">(18)</ref>] that increased the interest in therapeutic utility of D 1 agonists.</s><s>These antagonists have, however, continued to impact neuroscience because 11 C-SCH-23390 and its closely related analog, 11 C-NNC-112 (Figure <ref type="figure" target="#fig_1">2</ref>), have become the mainstay PET ligands for clinical imaging of D 1 Rs <ref type="bibr" target="#b18">(19,</ref><ref type="bibr" target="#b19">20)</ref>, including studies which demonstrate direct relationships between D 1 R binding potential and cognitive function <ref type="bibr" target="#b20">(21,</ref><ref type="bibr" target="#b21">22)</ref> (see below).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Indirect activation of dopamine receptors</head><p><s>A variety of strategies have been employed to try to enhance DA actions in the dlPFC.</s><s>Mechanisms such as DA transporter (DAT) inhibition, increased DA synthesis or release, or inhibition of degradation by monoamine oxidases (MAO) or catechol-O-methyl-transferase (COMT) can augment the amount of synaptic catecholamines, including DA.</s><s>Yet therapeutically, generalized increases in catecholamine actions (e.g., levodopa, methylphenidate, amphetamines) will tend to cause undesired side effects, especially in many target populations who are susceptible to exacerbation of psychoses, to substance abuse, etc., that can be affected by activation of D 2 R. As DAT expression is low in the dlPFC, it has been hypothesized that COMT might be an excellent target for more selective regional activation, albeit of all catecholamine receptors <ref type="bibr" target="#b22">(23,</ref><ref type="bibr" target="#b23">24)</ref>.</s><s>Unfortunately, the three approved COMT inhibitors (tolcapone, entacapone, ocicapone) <ref type="bibr" target="#b24">(25,</ref><ref type="bibr" target="#b25">26)</ref>, while useful for slowing the peripheral degradation of levodopa in treatment of Parkinson's disease, have little brain penetration <ref type="bibr" target="#b26">(27,</ref><ref type="bibr" target="#b27">28)</ref>.</s><s>Rigorous testing of this hypothesis must await a non-toxic brain penetrant COMT inhibitor.</s><s>This suggested that targeting specific dopamine receptors, especially the D 1 R, might be a useful strategy.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Concepts relevant to dopamine receptor ligands</head><p><s>Clinical and basic neuroscientists are generally aware of the classical issues in the use of receptor-targeting drugs, specifically the affinity of the drug for the desired versus off-target receptors, and the property of the drug (e.g., agonist or antagonist) at the primary targeted receptor.</s><s>There are two directly important subtleties that can often impact interpretation, but are less widely appreciated.</s><s>The classical one is partial agonism, reflecting that a particular drug even at near-saturating concentrations will only activate the target receptor to some fraction of the natural ligand of the receptor.</s><s>(The degree to which a drug activates a receptor relative to the natural ligand for the receptor is called intrinsic activity.)</s><s>Classically, partial agonists are also known to be partial antagonists, and may inhibit the actions of the natural ligand.</s><s>The second and now generally accepted concept is called "functional selectivity" or "ligand bias" <ref type="bibr" target="#b28">(29)</ref><ref type="bibr" target="#b29">(30)</ref><ref type="bibr" target="#b30">(31)</ref>.</s><s>Essentially, this concept reflects the fact that some drugs can have very diverse functional effects on different signaling pathways mediated by a single receptor.</s><s>In the extreme, this can even be full activation (full agonism) of one signaling pathway of a receptor, and pure antagonism at another pathway of the same receptor even in the same cell <ref type="bibr" target="#b31">(32,</ref><ref type="bibr" target="#b32">33)</ref>.</s><s>This differential activation may also be expressed as large differences in potency at two different signaling pathways <ref type="bibr" target="#b28">(29,</ref><ref type="bibr" target="#b33">34)</ref>.</s></p><p><s>Finally, the concept of allosteric drugs (i.e., ligands acting at sites on the receptor distant from the binding site of endogenous ligands) is well known in biological psychiatry as the mechanism of action at ionotropic receptors (e.g., benzodiazepines at GABA A receptors).</s><s>Recently, there has been a surge of activity in the discovery of allosteric ligands for G protein-coupled receptors, and this is beginning to impact DA receptors.</s><s>These three concepts will be relevant to specific compounds discussed below.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Non-selective drugs with D 1 agonist properties</head><p><s>There is sometimes confusion when there is discussion of approved "DA agonists," and a brief discussion may be useful All of the currently approved "dopamine agonists" are selective to a greater or lesser extent for the D 2 -like versus the D 1 -like receptors.</s><s>Indeed, many (e.g., ropinirole, pramipexole, bromocriptine, cabergoline) are devoid of D 1 agonist activity, though there are three exceptions.</s><s>Apomorphine has D 1 R high intrinsic activity, but is selective for D 2 R; its activity at D 1 R may be why it is effective in advanced Parkinson's Disease (PD) <ref type="bibr" target="#b34">(35)</ref>.</s><s>Unfortunately, its poor pharmaceutical properties and D 2 R side effects make it unsuitable for treating cognition <ref type="bibr" target="#b35">(36)</ref><ref type="bibr" target="#b36">(37)</ref><ref type="bibr" target="#b37">(38)</ref><ref type="bibr" target="#b38">(39)</ref><ref type="bibr" target="#b39">(40)</ref><ref type="bibr" target="#b40">(41)</ref>.</s><s>Rotigotine has similar properties.</s><s>Pergolide, which will soon be unavailable, has modest D 1 partial agonist activity <ref type="bibr" target="#b41">(42,</ref><ref type="bibr" target="#b42">43)</ref>, and has been used for cognitive experiments as discussed below.</s><s>Lastly, CY-208,243 had modest selectivity for D 1 versus D 2 receptors (44), and D 1 -dependent antiparkinsonian actions in monkeys (45-47), (but not in humans <ref type="bibr" target="#b47">(48)</ref>), but its development ceased.</s><s>Ergolines are generally promiscuous for monoamine receptors, and many activate serotonin 5-HT 2B receptors (49) making them unsuitable for human studies.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Selective D 1 agonists used in laboratory animal studies</head><p><s>The prototype of selective D 1 agonists is SKF-38393 (Figure <ref type="figure" target="#fig_2">3</ref>), first reported nearly forty years ago <ref type="bibr" target="#b49">(50,</ref><ref type="bibr" target="#b50">51)</ref>, which is a member of the 1-phenyl-tetrahydro-benzazepine chemotype that has yielded dozens of experimental compounds <ref type="bibr" target="#b51">(52)</ref><ref type="bibr" target="#b52">(53)</ref><ref type="bibr" target="#b53">(54)</ref>.</s><s>SKF-38393 probably has been the most widely used D 1 agonist, but although it is quite selective, it is only a partial agonist with modest intrinsic activity in canonical signaling pathways <ref type="bibr" target="#b50">(51,</ref><ref type="bibr" target="#b54">(55)</ref><ref type="bibr" target="#b55">(56)</ref><ref type="bibr" target="#b56">(57)</ref>.</s><s>When this is ignored in interpreting pharmacological studies, it may lead to erroneous conclusions.</s><s>SKF-81297 (Figure <ref type="figure" target="#fig_2">3</ref>) is another commonly used member of the benzazepine chemotype that has much higher intrinsic activity than SKF-38393 <ref type="bibr" target="#b56">(57)</ref>, and has been a useful tool for in vitro and animal experimentation.</s></p><p><s>Two D 1 agonists from this class, SPD-451 and SKF-83959, have been particularly provocative because both were proposed to be functionally selective D 1 R ligands that had high intrinsic activity for D 1 R-activation of phospholipase C and low intrinsic activation for the canonical cAMP-mediated signaling.</s><s>Extensive studies with SKF-83959 also led to the hypothesis that its novel functionally selective signaling was mediated by a D 1 D 2 receptor heterodimer <ref type="bibr" target="#b57">(58)</ref>.</s><s>The development of SPD-451, originally advanced by CeNeS Pharmaceuticals plc and later Shire, has apparently ceased.</s><s>SKF-83959 has never been advanced to humans, but has been widely used experimentally because of these purported novel properties <ref type="bibr" target="#b58">(59)</ref><ref type="bibr" target="#b59">(60)</ref><ref type="bibr" target="#b60">(61)</ref><ref type="bibr" target="#b61">(62)</ref>.</s><s>Unfortunately, recent data suggest that this compound is actually similar to other benzazepine partial agonists, and is neither highly functionally selective, nor works through a D 1 /D 2 heterodimer <ref type="bibr" target="#b62">(63)</ref><ref type="bibr" target="#b63">(64)</ref><ref type="bibr" target="#b64">(65)</ref>.</s><s>As a class, the benzazepines also have poor oral bioavailability and short duration of action due to the inherent catechol group <ref type="bibr" target="#b65">(66)</ref>, and in addition, many of the members of this group have a propensity to cause seizures <ref type="bibr" target="#b66">(67)</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Non-benzazepine centrally available full D 1 agonists</head><p><s>The first full D 1 agonists were fenoldopam and SKF-89626 (Figure <ref type="figure" target="#fig_2">3</ref>), but neither compound was brain penetrable <ref type="bibr" target="#b56">(57,</ref><ref type="bibr" target="#b67">68,</ref><ref type="bibr" target="#b68">69)</ref>.</s><s>The first selective centrally available D 1 R full agonist was dihydrexidine (Figure <ref type="figure" target="#fig_2">3</ref>) (55-57, 70-73), and it has been a very useful tool in testing hypotheses about the roles of D 1 R receptors, such as for antiparkinsonian therapy <ref type="bibr" target="#b73">(74)</ref> or effects on cognition <ref type="bibr" target="#b74">(75)</ref>.</s><s>Although dihydrexidine is only ten-fold D 1 :D 2 selective <ref type="bibr" target="#b71">(72)</ref>, it has profound D 2 R functional selectivity <ref type="bibr" target="#b31">(32,</ref><ref type="bibr" target="#b32">33)</ref>, and its behavioral effects generally lack D 2 R properties <ref type="bibr" target="#b75">(76)</ref>.</s><s>Dihydrexidine, however, has two major limitations for human experimentation: it has very little oral bioavailability, and is metabolized very rapidly.</s></p><p><s>Chronologically, the next compounds of importance were A-68930 and A-77636 (Figure <ref type="figure" target="#fig_2">3</ref>), two selective D 1 agonists from the novel isochroman chemotype <ref type="bibr" target="#b76">(77,</ref><ref type="bibr" target="#b77">78)</ref>.</s><s>A-68930 caused seizures <ref type="bibr" target="#b78">(79)</ref>, but A-77636 has been widely used experimentally because it appeared to have overcome the bioavailability problems of dihydrexidine and had a long duration of action.</s><s>In murine and primate species, both compounds caused profound antiparkinsonian effects like dihydrexidine <ref type="bibr" target="#b79">(80,</ref><ref type="bibr" target="#b80">81)</ref>, but both also caused a profound and rapid tolerance <ref type="bibr" target="#b77">(78,</ref><ref type="bibr" target="#b81">(82)</ref><ref type="bibr" target="#b82">(83)</ref><ref type="bibr" target="#b83">(84)</ref>.</s><s>Both the tolerance and seizures are potential developmental liabilities that are discussed below.</s></p><p><s>Because of the tolerance caused by A-77636, Abbott laboratories next reported A-86929 (Figure <ref type="figure" target="#fig_2">3</ref>) and its diacetyl prodrug ABT-431 (adrogolide) (Abbott Laboratories).</s><s>A86929 is similar in structure and pharmacological properties to dihydrexidine <ref type="bibr" target="#b84">(85,</ref><ref type="bibr" target="#b85">86)</ref>.</s><s>Like dihydrexidine, ABT-431 caused dramatic antiparkinsonian effects <ref type="bibr" target="#b73">(74,</ref><ref type="bibr" target="#b85">86,</ref><ref type="bibr" target="#b86">87)</ref>, but like dihydrexidine, even the prodrug ABT-431 had poor oral bioavailability.</s><s>ABT-431 was outlicensed to Drug Abuse Sciences as a potential anti-cocaine therapy, but development ceased for reasons that are not public.</s><s>Another compound that failed development was dinapsoline, a D 1 :D 2 agonist with high D 1 R intrinsic activity and significant functional selectivity at D 2 receptors.</s><s>Like dihydrexidine, its behavioral actions in animal models of Parkinson's models were D 1 R , not D 2 R, dependent <ref type="bibr" target="#b87">(88)</ref><ref type="bibr" target="#b88">(89)</ref><ref type="bibr" target="#b89">(90)</ref>.</s><s>Unfortunately, there have not been newer compounds with marked advantages reported recently.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Challenges and opportunities for clinical development</head><p><s>A major problem in development of selective full D 1 agonists has been oral bioavailability.</s><s>All reported chemotypes for selective full D 1 agonists contain a catechol moiety (as in dopamine) that, at least to date, seems necessary for full D 1 R agonism but which causes predictable problems in bioavailability.</s><s>In the few cases where drugs have reasonable bioavailability (e.g., A-77636 <ref type="bibr" target="#b77">(78)</ref> or dinapsoline <ref type="bibr" target="#b88">(89)</ref>), the compounds had high plasma protein binding and low free fraction, and unbound clearance remains high.</s><s>A-77636 also has near irreversible binding to the D 1 R in vivo <ref type="bibr" target="#b90">(91)</ref>.</s><s>Addressing these pharmacokinetic issues is essential for any major advance.</s></p><p><s>There are two primary safety concerns with this class.</s><s>Some D 1 agonists have been reported to induce seizures or lower seizure thresholds, and D 1 activation seems to be critical as they are prevented by D 1 R antagonists and not seen in D 1 R knockout mice <ref type="bibr" target="#b66">(67)</ref>.</s><s>This is drug specific, however, as the full D 1 agonist A-77636 does not induce seizures, unlike its analog A-68930 <ref type="bibr" target="#b78">(79)</ref>.</s><s>Similarly, monotherapy with dihydrexidine or ABT-431 has not been associated with epileptogenic potential in rats, mice, or primates.</s><s>Thus, D 1 R activation alone is not sufficient to cause seizures, and the involved mechanism(s) and the relative safety margin of D 1 agonists as a class are unclear.</s></p><p><s>The other D 1 R-related safety concern is hypotension, the reason for the premature termination of the first pilot human trial of dihydrexidine <ref type="bibr" target="#b91">(92)</ref>.</s><s>These effects are probably mediated by peripheral D 1 R in the kidney and elsewhere in the cardiovascular system <ref type="bibr" target="#b92">(93)</ref>.</s><s>Because the cardiovascular system can respond rapidly to such challenges, this may not be limiting if blood concentrations of the drug do not rise too rapidly as suggested by recent clinical studies <ref type="bibr" target="#b57">(58,</ref><ref type="bibr" target="#b93">94,</ref><ref type="bibr" target="#b94">95)</ref>.</s></p><p><s>Finally, a non-safety issue, rapid tolerance, may limit use of D 1 agonists.</s><s>During antiparkinsonian studies in both murine and primate species, the dramatic effectiveness of A77636 and A68930 was rapidly (within 24-48 h) lost <ref type="bibr" target="#b81">(82,</ref><ref type="bibr" target="#b95">96)</ref>.</s><s>Indeed, a single dose of A77636 results in almost complete tolerance <ref type="bibr" target="#b83">(Blanchet et al., 1996)</ref>, hypothesized to be due to rapid desensitization probably resulting from irreversible binding to the D 1 R (91).</s><s>On the other hand, the fact that dinapsoline (a drug that does not bind irreversibly) did not cause tolerance with once or twice daily subcutaneous injection, but did with constant minipump infusion <ref type="bibr" target="#b88">(89)</ref>, suggests more complicated mechanisms.</s><s>When a clinical candidate is identified, it will be important to determine the conditions under which it may cause this rapid tolerance.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Dopamine changes in schizophrenia</head><p><s>The initial hypotheses about the mechanism of positive symptoms of schizophrenia were based in large measure on pharmacological data in which the clinical effectiveness of antipsychotic drugs correlated well with their affinity for D 2 -like receptors <ref type="bibr" target="#b96">(97)</ref>.</s><s>Even today, all approved antipsychotics require as part of their pharmacology interactions with the D 2 R. The antipsychotic drugs are generally effective against positive symptoms (e.g., delusions, hallucinations, etc.) <ref type="bibr" target="#b97">(98,</ref><ref type="bibr" target="#b98">99)</ref>.</s><s>A variety of clinical experimental studies showing that sensitivity to stimulant medications <ref type="bibr" target="#b99">(100)</ref><ref type="bibr" target="#b100">(101)</ref><ref type="bibr" target="#b101">(102)</ref><ref type="bibr" target="#b102">(103)</ref>, increases in DA synthesis <ref type="bibr" target="#b103">(104)</ref><ref type="bibr" target="#b104">(105)</ref><ref type="bibr" target="#b105">(106)</ref>, and predictive utility of baseline occupancy of striatal D 2 Rs (107) suggest that increased activity in striatal DA neurotransmission is associated with positive symptoms <ref type="bibr" target="#b107">(108)</ref>, explaining the efficacy of D 2 R antagonists.</s></p><p><s>Conversely, effects on negative symptoms are limited <ref type="bibr" target="#b108">(109)</ref><ref type="bibr" target="#b109">(110)</ref><ref type="bibr" target="#b110">(111)</ref><ref type="bibr" target="#b111">(112)</ref>. Effects on neurocognitive deficits (e.g., working memory, verbal memory, attention, executive functioning) have also been reported <ref type="bibr" target="#b0">(1,</ref><ref type="bibr" target="#b1">2,</ref><ref type="bibr" target="#b112">(113)</ref><ref type="bibr" target="#b113">(114)</ref><ref type="bibr" target="#b114">(115)</ref><ref type="bibr" target="#b115">(116)</ref><ref type="bibr" target="#b116">(117)</ref><ref type="bibr" target="#b117">(118)</ref>, but have been small <ref type="bibr" target="#b98">(99)</ref>.</s><s>The relative lack of effects of antipsychotic medications on cognition are particularly important given that approximately 75% of patients with schizophrenia have clinically meaningful deficits in at least two cognitive domains, and 90% have deficits in at least one domain <ref type="bibr" target="#b118">(119)</ref>.</s><s>In addition, cognitive deficits are present at illness onset <ref type="bibr" target="#b119">(120)</ref>, persist over time <ref type="bibr" target="#b120">(121)</ref>, and are more predictive of overall psychosocial functioning than are positive symptoms <ref type="bibr" target="#b121">(122,</ref><ref type="bibr" target="#b122">123)</ref>.</s></p><p><s>Negative symptoms and cognitive deficits are thought to be related, at least in part, to a cortical DA deficit <ref type="bibr" target="#b123">(124)</ref><ref type="bibr" target="#b124">(125)</ref><ref type="bibr" target="#b125">(126)</ref>.</s><s>An abundance of preclinical and other indirect data suggest that hypodopaminergic function in the dlPFC may be associated with these symptom domains.</s><s>As described above, either DA depletion in the dlPFC, or DA antagonists, impair cognitive function <ref type="bibr" target="#b2">(3,</ref><ref type="bibr" target="#b126">(127)</ref><ref type="bibr" target="#b127">(128)</ref><ref type="bibr" target="#b128">(129)</ref>.</s><s>D 1 agonists can reverse these deficits (75), although higher doses of D 1 agonists impair working memory function, leading to inverted-U dose-response curves <ref type="bibr" target="#b74">(75,</ref><ref type="bibr" target="#b129">(130)</ref><ref type="bibr" target="#b130">(131)</ref><ref type="bibr" target="#b131">(132)</ref><ref type="bibr" target="#b132">(133)</ref>.</s></p><p><s>Evidence for DA receptor hypofunction in PFC in schizophrenia comes from several lines of research.</s><s>There are decreased levels of DA metabolites in the cerebrospinal fluid of schizophrenic individuals, and these are correlated with poor working memory performance <ref type="bibr" target="#b133">(134,</ref><ref type="bibr" target="#b134">135)</ref>.</s><s>DA agonists may be able to ameliorate the patterns of activation in dlPFC during these tasks <ref type="bibr" target="#b135">(136)</ref>.</s><s>Genetic variations of the COMT gene that cause increased metabolism of DA are also associated with impaired PFC function, and a greater risk of schizophrenia <ref type="bibr" target="#b136">(137)</ref>.</s><s>One post-mortem study of tyrosine hydroxylase immunolabeling showed differences in DA innervation of the dlPFC in patients <ref type="bibr" target="#b137">(138)</ref>, whereas postmortem studies of D 1 Rs have not shown differences <ref type="bibr" target="#b138">(139,</ref><ref type="bibr" target="#b139">140)</ref>.</s><s>PET labeling studies of cortical D 1 R density have not yielded consistent results <ref type="bibr" target="#b20">(21,</ref><ref type="bibr" target="#b140">(141)</ref><ref type="bibr" target="#b141">(142)</ref><ref type="bibr" target="#b142">(143)</ref>.</s><s>More recently, Slifstein et al. <ref type="bibr" target="#b143">(144)</ref> reported decreased amphetamine-induced DA release in the dlPFC in patients with schizophrenia, further supporting the hypothesis of cortical hypodopaminergia in this disorder.</s><s>Thus, there is a major unmet need for the development of new psychopharmacologic agents for schizophrenia, in particular for cognitive deficits.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Clinical studies of D 1 agonists</head><p><s>Single doses of the full D 1 agonist dihydrexidine have been given both to individuals with PD <ref type="bibr" target="#b91">(92)</ref> and with schizophrenia <ref type="bibr" target="#b57">(58,</ref><ref type="bibr" target="#b93">94)</ref>.</s><s>In the schizophrenia study, patients were randomized in a cross-over design between dihydrexidine and placebo <ref type="bibr" target="#b57">(58,</ref><ref type="bibr" target="#b93">94)</ref>.</s><s>Side effects were minimal, no orthostatic changes were observed, and increased perfusion (i.e., via fMRI) in bilateral PFC was noted <ref type="bibr" target="#b57">(58,</ref><ref type="bibr" target="#b93">94)</ref>, but with only a trend for improvements on the Controlled Oral Word Association Test or the Hopkins Verbal Learning Test.</s><s>Another study used the mixed D 2 :D 1 agonist pergolide in 25 subjects with schizotypal personality disorder and compared placebo and drug on neuropsychological performance <ref type="bibr" target="#b144">(145)</ref>.</s><s>The pergolide group showed improvements in visual-spatial working memory, executive function, and verbal learning and memory, and suggested that drugs with D 1 R properties may provide benefit for the cognitive abnormalities of schizophrenia spectrum disorders.</s></p><p><s>Because of the data on dlPFC hypofunction and D 1 Rs, the effects of the active (+)enantiomer <ref type="bibr" target="#b145">(146)</ref> of dihydrexidine (numbered DAR-0100A) was studied as an add-on treatment for cognitive enhancement in schizophrenia.</s><s>A PET receptor occupancy study in non-human primates using [ 11 C]NNC112 and [ 11 C]raclopride to examine D 1 R and D 2 R/ D 3 R, respectively, showed dose-dependent selective binding of DAR-0100A to the D 1 R <ref type="bibr" target="#b146">(147)</ref>.</s><s>A trial of 49 clinically stable individuals with schizophrenia involved three weeks of intermittent treatment with either placebo (normal saline), or a high (15 mg, the MTD) or low dose (0.5 mg) of DAR-0100A.</s><s>These doses were chosen to avoid drug-induced hypotension <ref type="bibr" target="#b91">(92)</ref>.</s><s>Because of the rapid metabolism in man <ref type="bibr" target="#b91">(92)</ref>, blood levels of DAR-0100A were below limits of quantification, suggesting that these doses of DAR-0100A achieved only minimal engagement of the D 1 R, No treatment effects were found on BOLD fMRI signals during working memory tasks, on working memory domains of the MATRICS battery, or on clinical measures.</s><s>Conversely, some improvement on the CogState Schizophrenia Battery was seen in the high dose group, as well as improvement in attention on the MATRICS battery in both treatment groups.</s><s>Differences in patient population (especially medication status) may explain the more positive findings of Rosell et al. <ref type="bibr" target="#b94">(95)</ref> who administered three 15 mg doses of DAR-0100A or placebo to 16 individuals with schizotypal personality disorder.</s><s>Improvement was observed in working memory on the Paced Auditory Serial Audition Task (PASAT) and on the 2-Back to 0-back ratio, although this ratio was improved in part due to worse performance on the 0-back condition.</s><s>Although these results are not totally conclusive, they suggest a pro-cognitive effect of a full D 1 agonist in schizophrenia.</s><s>Importantly, that unquantifiable blood levels of DAR-0100A (although nonspecific metabolites were qualitatively observed at levels commensurate with the two doses) were observed suggests that these doses of DAR-0100A achieved only minimal engagement of the D 1 R, likely explaining these mixed results.</s><s>These results certainly suggest studies of better D 1 agonists (i.e., that achieve more target engagement) are needed to more fully test the efficacy of this mechanism for cognitive enhancement in schizophrenia and reconcile the mixed findings from these trials.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Future opportunities</head><p><s>As can be gleaned from the material above, one major goal should be the discovery of safe and highly bioavailable (probably non-catechol containing), full D 1 agonists.</s><s>The accumulating evidence for a potential therapeutic role of D 1 agonists in several areas will hopefully spur both pharmaceutical companies and academic groups to jump existing hurdles.</s><s>Patent activity suggests progress toward structurally novel agents, but none have been disclosed in the peer-reviewed literature at this time.</s><s>There are, however, some alternate approaches that may be useful.</s></p><p><s>A D 1 positive allosteric modulator (PAM) would enhance the endogenous actions of DA at D 1 R, and recently, the first published preclinical breakthrough in this area was reported for two series of PAMs (see Figure <ref type="figure" target="#fig_3">4</ref>) that are active in vitro <ref type="bibr" target="#b147">(148)</ref>.</s><s>One of the compounds was selective for D 1 R, but had much lower activity at the murine vs. the human D 1 R.</s><s>A patent from Eli-Lilly also reports an additional chemotype for D 1 PAMs that potentiate relevant in vivo signals including locomotor activity and release of acetylcholine in PFC <ref type="bibr" target="#b148">(149)</ref>.</s></p><p><s>Another intriguing possibility is functionally selective D 1 ligands.</s><s>As an example, in most assays, SKF-38393 is a partial agonist because it has much less intrinsic activity than DA or dihydrexidine.</s><s>Consistent with classical pharmacology, this would explain why SKF-38393 is a much less effective antiparkinsonian drug than dihydrexidine.</s><s>Yet in some systems, the two compounds are equally effective physiologically <ref type="bibr" target="#b74">(75,</ref><ref type="bibr" target="#b149">150)</ref>.</s><s>These data suggest that SKF-38393, while a partial agonist at most commonly tested D 1 R mediated signaling pathways, may have higher intrinsic activity in others.</s><s>There is significant functional selectivity even among experimental compounds considered "full agonists" <ref type="bibr" target="#b89">(90,</ref><ref type="bibr" target="#b90">91)</ref>.</s><s>Thus, discovery of new highly-biased D 1 R ligands may be an important route to more selective actions in vivo, that also avoid problems like seizures and rapid tolerance.</s></p><p><s>Finally, to maximize the beneficial effects of D 1 R stimulation on dlPFC function in schizophrenia will require addressing the "inverted U" dose-response curves seen in vivo.</s><s>As noted earlier, one D 1 R mechanism involves increased cAMP opening of HCN channels that can suppress all firing if doses are too high.</s><s>Optimal effects on working memory can be achieved by careful dose titration, but this will be challenging because of inter-individual differences in drug metabolism and distribution.</s><s>Besides a D 1 R PAM or functionally selective D 1 R orthosteric ligand, it may be that a D 1 R selective compound with more "dopamine-like" affinity would be useful, as this might attenuate excessive cAMP-mediated opening of HCN channels.</s><s>The potential for large effect sizes shown by existing data makes these challenges worthy of tackling.</s><s>A. Localization of D 1 R in layer III dlPFC pyramidal cell networks.</s><s>Pyramidal cells interconnect via NMDAR synapses on spines, with permissive actions from nicotinic α7 receptors (nic-α7R).</s><s>Immunoelectron microscopy has shown that D 1 R are concentrated on dendritic spines, where they can be seen directly within the synapse (magenta), and near the synapse where they often co-localize with HCN or KCNQ potassium channels (red).</s><s>The open state of both of these channels is increased by cAMP-PKA signaling.</s><s>Physiological recordings from monkeys indicate that D 1 R activates feedforward cAMP-PKA-calcium signaling, which opens K + channels and weakens nearby synaptic inputs (red).</s><s>At optimal doses this sculpts away noise from irrelevant inputs, but at higher doses, e.g. as occurs during stress, it causes nonspecific suppression of Delay cell firing and loss of working memory.</s><s>Feedforward cAMP-calcium signaling is held in check by the phosphodiesterase, PDE4A, which is anchored in place by DISC1 (Disrupted In Schizophrenia).</s><s>Studies in nonprimate species suggest that D 1 R within the synapse phosphorylate NMDAR via activation of cAMP-PKA and PKC signaling; this maintains NMDAR in the synaptic membrane and strengthens connections (magenta).</s><s>There are also D 1 R on glutamate axon terminals that may reduce glutamate release (purple).</s><s>For detailed description, see Arnsten et al, 2015.</s><s>The asterisk indicates the spine apparatus, the extension of the smooth endoplasmic reticulum into the spine.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>B.</head><p><s>A schematic illustration of the DA D 1 R inverted U influence on the "memory fields" of dlPFC Delay cells.</s><s>For details, see <ref type="bibr" target="#b4">(5)</ref>.</s><s>Under optimal arousal conditions, Delay cells generate persistent representations of visual space, displaying high rates of firing (orangered) to the memory of one spatial location, and low rates of firing (blue) to the memory of all other spatial locations.</s><s>When there is no D 1 R stimulation, Delay cells have little firing.</s><s>Low levels of D 1 R stimulation appear to be excitatory, e.g.</s><s>phosphorylating NMDAR to increase their trafficking into the synapse <ref type="bibr" target="#b6">(7)</ref>.</s><s>This can produce noisy firing for all directions, as represented by the generalized green-orange coloring of the memory field.</s><s>With optimal levels of D 1 R stimulation, there are additional sculpting actions, gating out "noise", e.g. by opening a subset of HCN channels.</s><s>At still higher levels of D 1 R stimulation (e.g. as occurs during stress), there is excessive HCN channel opening and Delay cell firing is generally suppressed.</s><s>Under these conditions the neuron is not able to generate persistent representations of visual space.</s><s>PAMs may offer an advantage over orthosteric (direct) agonists by interacting with endogenous dopamine tone, and as such, may possibly avoid biphasic effects currently seen with direct D 1 agonists.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1 .</head><label>1</label><figDesc><div><p><s>Figure 1.</s><s>Schematic illustration of DA D 1 R influences on Delay cell firing in layer III of the primate dlPFC</s></p></div></figDesc><graphic coords="19,191.64,62.00,288.72,348.19" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 2 .</head><label>2</label><figDesc><div><p><s>Figure 2. Structures of selective D 1 antagonists and PET ligandsThe site of radiolabeling is shown by the asterisk.</s><s>The most pharmacologically active isomer is shown, although these compounds are sometimes used as racemates.</s></p></div></figDesc><graphic coords="21,119.64,62.00,432.72,180.58" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Figure 3 .</head><label>3</label><figDesc><div><p><s>Figure 3. Examples of important experimental D 1 agonists [Top Row] SKF-38393 (partial agonist) and SKF-82958 (full agonist) are phenylbenzazepines.</s><s>SKF-89626 had higher intrinsic activity than SKF-38393, but lacked BBB permeability.</s><s>CY208243 is a high D 1 intrinsic activity ergoline.</s><s>[Bottom row] Four full D 1 agonists from four different chemotypes: A-77636, A-86829 (the active compound of the diacetyl prodrug ABT-431), dihydrexidine (DAR-0100A), and dinapsoline.</s><s>The most pharmacologically active isomer is shown in all cases, although these compounds are sometimes used as racemates.</s></p></div></figDesc><graphic coords="22,119.97,62.00,432.07,251.28" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Figure 4 .</head><label>4</label><figDesc><div><p><s>Figure 4. Structures of D 1 positve allosteric modulators (PAMs)</s></p></div></figDesc><graphic coords="23,119.76,62.00,432.48,328.32" type="bitmap" /></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_0"><p><s>Biol Psychiatry.</s><s>Author manuscript; available in PMC 2018 January 01.</s></p></note>
		</body>
		<back>

			<div type="acknowledgement">
<div><head>Acknowledgments</head><p>This work was supported by <rs type="funder">PHS</rs> grants <rs type="grantNumber">DP1AG047744</rs> to AFTA; and <rs type="grantNumber">MH040537</rs>, <rs type="grantNumber">MH082441</rs>, and <rs type="grantNumber">NS039036</rs> to RBM.</p></div>
			</div>
			<listOrg type="funding">
				<org type="funding" xml:id="_vbDgNGe">
					<idno type="grant-number">DP1AG047744</idno>
				</org>
				<org type="funding" xml:id="_F52nPST">
					<idno type="grant-number">MH040537</idno>
				</org>
				<org type="funding" xml:id="_TnKf77r">
					<idno type="grant-number">MH082441</idno>
				</org>
				<org type="funding" xml:id="_f4JqDcj">
					<idno type="grant-number">NS039036</idno>
				</org>
			</listOrg>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Cognitive Effects of Antipsychotic Drugs in First-Episode Schizophrenia and Schizophreniform Disorder: A Randomized, Open-Label Clinical Trial (EUFEST)</title>
		<author>
			<persName><forename type="first">M</forename><surname>Davidson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Galderisi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Weiser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Werbeloff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">W</forename><surname>Fleischhacker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Keefe</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Psychiat</title>
		<imprint>
			<biblScope unit="volume">166</biblScope>
			<biblScope unit="page" from="675" to="682" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note>PubMed: 19369319</note>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Keefe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">G</forename><surname>Silva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">O</forename><surname>Perkins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Lieberman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Schizophr Bull</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="201" to="222" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
	<note>PubMed: 10416727</note>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Brozoski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Brown</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">E</forename><surname>Rosvold</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">S</forename><surname>Goldman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">205</biblScope>
			<biblScope unit="page" from="929" to="932" />
			<date type="published" when="1979">1979</date>
		</imprint>
	</monogr>
	<note>PubMed: 112679</note>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Distinctive transcriptome alterations of prefrontal pyramidal neurons in schizophrenia and schizoaffective disorder</title>
		<author>
			<persName><forename type="first">D</forename><surname>Arion</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Corradi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Tang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Datta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Boothe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>He</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Psychiatry</title>
		<imprint>
			<date type="published" when="2015-01-06">2015 Jan 6</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Dopamine&apos;s actions in primate prefrontal cortex: Challenges for treating cognitive disorders</title>
		<author>
			<persName><forename type="first">Aft</forename><surname>Arnsten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">D</forename><surname>Paspalas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacological Rev</title>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="page" from="681" to="696" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Nicotinic α7 receptors enhance NMDA cognitive circuits in dorsolateral prefrontal cortex</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">D</forename><surname>Paspalas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">E</forename><surname>Jin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Picciotto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Aft</forename><surname>Arnsten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Wang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Nat Acad Sci USA</title>
		<imprint>
			<biblScope unit="volume">110</biblScope>
			<biblScope unit="page" from="12078" to="12083" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note>PubMed: 23818597</note>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Dopamine D(1) receptor-mediated enhancement of NMDA receptor trafficking requires rapid PKC-dependent synaptic insertion in the prefrontal neurons</title>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">C</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Hu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Gao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">Q</forename><surname>Huang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurochem</title>
		<imprint>
			<biblScope unit="volume">114</biblScope>
			<biblScope unit="page" from="62" to="73" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note>PubMed: 20374423</note>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Reversal of antipsychotic-induced working memory deficits by short-term dopamine D1 receptor stimulation</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Castner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">V</forename><surname>Williams</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">S</forename><surname>Goldman-Rakic</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">287</biblScope>
			<biblScope unit="page" from="2020" to="2022" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
	<note>PubMed: 10720329</note>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">SCH 23390, a potential benzazepine antipsychotic with unique interactions on dopaminergic systems</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">C</forename><surname>Iorio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Barnett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">H</forename><surname>Leitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">P</forename><surname>Houser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Korduba</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of Pharmacology and Experimental Therapeutics</title>
		<imprint>
			<biblScope unit="volume">226</biblScope>
			<biblScope unit="page">6135795</biblScope>
			<date type="published" when="1983">1983</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">SCH 23390: the first selective dopamine D1-like receptor antagonist</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Bourne</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">CNS drug reviews</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="399" to="414" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
	<note>PubMed: 11830757</note>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Synthesis and receptor affinities of some conformationally restricted analogs of the dopamine D1 selective ligand</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Berger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Clader</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Hou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Chipkin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">T</forename><surname>Mcphail</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of Medicinal Chemistry</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="issue">5R</biblScope>
			<biblScope unit="page" from="1913" to="1921" />
			<date type="published" when="1989">8chloro-2,3,4,5-tetrahydro-3. 1989</date>
		</imprint>
	</monogr>
	<note>-methyl-5-phenyl-1H-3-benzazepin-7-ol. PubMed: 2666667</note>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Lack of apparent antipsychotic effect of the D1-dopamine receptor antagonist SCH39166 in acutely ill schizophrenic patients</title>
		<author>
			<persName><forename type="first">P</forename><surname>Karlsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Farde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Harnryd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Sedvall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">A</forename><surname>Wiesel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychopharmacology (Berl)</title>
		<imprint>
			<biblScope unit="volume">121</biblScope>
			<biblScope unit="page" from="309" to="316" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
	<note>PubMed: 8584611</note>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">A pilot study of the safety and tolerance of SCH 39166 in patients with schizophrenia</title>
		<author>
			<persName><forename type="first">A</forename><surname>Labelle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>De Beaurepaire</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Boulay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Naber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">D</forename><surname>Jones</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">R</forename><surname>Barnes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of Psychiatry and Neuroscience</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="93" to="94" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
	<note>PubMed: 9549248</note>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Differential effects of the D1-DA receptor antagonist SCH39166 on positive and negative symptoms of schizophrenia</title>
		<author>
			<persName><forename type="first">Den</forename><surname>Boer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Van Megen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Fleischhacker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">W</forename><surname>Louwerens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Slaap</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">R</forename><surname>Westenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">G</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychopharmacology (Berl)</title>
		<imprint>
			<biblScope unit="volume">121</biblScope>
			<biblScope unit="page" from="317" to="322" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
	<note>PubMed: 8584612</note>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">An open trial of the D1 antagonist SCH 39166 in six cases of acute psychotic states</title>
		<author>
			<persName><forename type="first">R</forename><surname>De Beaurepaire</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Labelle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Naber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">D</forename><surname>Jones</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">R</forename><surname>Barnes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychopharmacology (Berl)</title>
		<imprint>
			<biblScope unit="volume">121</biblScope>
			<biblScope unit="page" from="323" to="327" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
	<note>PubMed: 8584613</note>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Effects of ecopipam, a selective dopamine D1 antagonist, on smoked cocaine self-administration by humans</title>
		<author>
			<persName><forename type="first">M</forename><surname>Haney</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Ward</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">W</forename><surname>Foltin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">W</forename><surname>Fischman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychopharmacology (Berl)</title>
		<imprint>
			<biblScope unit="volume">155</biblScope>
			<biblScope unit="page" from="330" to="337" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
	<note>PubMed: 11441422</note>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Randomized Controlled Trials of the D1/D5 Antagonist Ecopipam for Weight Loss in Obese Subjects</title>
		<author>
			<persName><forename type="first">A</forename><surname>Astrup</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">L</forename><surname>Greenway</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Ling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Pedicone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lachowicz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">D</forename><surname>Strader</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Obesity</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="1717" to="1731" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
	<note>PubMed: 17636090</note>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Effect of dopamine D1 receptor antagonist SCH23390 and D1 agonist A77636 on active allothetic place avoidance, a spatial cognition task</title>
		<author>
			<persName><forename type="first">A</forename><surname>Stuchlik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Vales</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Behavioural Brain Research</title>
		<imprint>
			<biblScope unit="volume">172</biblScope>
			<biblScope unit="page" from="250" to="255" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
	<note>PubMed: 16781786</note>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Carbon-11-NNC 112: a radioligand for PET examination of striatal and neocortical D1-dopamine receptors</title>
		<author>
			<persName><forename type="first">C</forename><surname>Halldin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Foged</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">H</forename><surname>Chou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Karlsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">G</forename><surname>Swahn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Sandell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of nuclear medicine: official publication, Society of Nuclear Medicine</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page" from="2061" to="2068" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">PET imaging of D1 receptors in striatal subdivisions in schizophrenia</title>
		<author>
			<persName><forename type="first">A</forename><surname>Abi-Dargham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Thompson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Urban</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Kegeles</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Narendran</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J NUCL MED MEETING ABSTRACTS</title>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="page">81</biblScope>
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Prefrontal dopamine D1 receptors and working memory in schizophrenia</title>
		<author>
			<persName><forename type="first">A</forename><surname>Abi-Dargham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Mawlawi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Lombardo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Gil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Martinez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Huang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">The Journal of neuroscience: the official journal of the Society for Neuroscience</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="3708" to="3719" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
	<note>PubMed: 11978847</note>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Changes in Cortical Dopamine D1 Receptor Binding Associated with Cognitive Training</title>
		<author>
			<persName><forename type="first">F</forename><surname>Mcnab</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Varrone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Farde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Jucaite</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Bystritsky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Forssberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">323</biblScope>
			<biblScope unit="page" from="800" to="802" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note>PubMed: 19197069</note>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Tolcapone effects on gating, working memory, and mood interact with the synonymous catechol-O-methyltransferase rs4818c/g polymorphism</title>
		<author>
			<persName><forename type="first">P</forename><surname>Roussos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">G</forename><surname>Giakoumaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Bitsios</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biol Psychiatry</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="page" from="997" to="1004" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note>PubMed: 19699472</note>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Lachman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">F</forename><surname>Papolos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Saito</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">M</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Szumlanski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Weinshilboum</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacogenetics</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="243" to="250" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
	<note>PubMed: 8807664</note>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in the rat</title>
		<author>
			<persName><forename type="first">M</forename><surname>Forsberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lehtonen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Heikkinen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Savolainen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Jarvinen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">T</forename><surname>Mannisto</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">The Journal of pharmacology and experimental therapeutics</title>
		<imprint>
			<biblScope unit="volume">304</biblScope>
			<biblScope unit="page" from="498" to="506" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note>PubMed: 12538800</note>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson&apos;s disease</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Ferreira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Rocha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Falcao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Santos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Pinto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Nunes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Neurol</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="815" to="825" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>PubMed: 25649051</note>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Tolcapone in Parkinson&apos;s disease: liver toxicity and clinical efficacy</title>
		<author>
			<persName><forename type="first">N</forename><surname>Borges</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Expert opinion on drug safety</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="69" to="73" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note>PubMed: 15709899</note>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Treatment of cognitive deficits associated with schizophrenia: potential role of catechol-O-methyltransferase inhibitors</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Apud</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Weinberger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">CNS drugs</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="535" to="557" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
	<note>PubMed: 17579498</note>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Functional selectivity and classical concepts of quantitative pharmacology</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Urban</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">P</forename><surname>Clarke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Von</forename><surname>Zastrow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Nichols</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Kobilka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Weinstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">The Journal of pharmacology and experimental therapeutics</title>
		<imprint>
			<biblScope unit="volume">320</biblScope>
			<biblScope unit="page" from="1" to="13" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
	<note>PubMed: 16803859</note>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Functional Effects of Novel Dopamine Ligands: Dihydrexidine and Parkinson&apos;s Disease as a First Step</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Mailman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Nichols</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Lewis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">L</forename><surname>Blake</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">P</forename><surname>Lawler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Dopamine Receptor Subtypes: From Basic Science to Clinical Application</title>
		<editor>
			<persName><forename type="first">P</forename><surname>Jenner</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">R</forename><surname>Demirdemar</surname></persName>
		</editor>
		<imprint>
			<publisher>IOS Stockton Press</publisher>
			<date type="published" when="1998">1998</date>
			<biblScope unit="page" from="64" to="83" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Ligand functional selectivity advances our understanding of drug mechanisms and drug discovery</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Mailman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Murthy</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropsychopharmacology</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="345" to="346" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note>PubMed: 20010712</note>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Functional selectivity of dopamine receptor agonists. I. Selective activation of postsynaptic dopamine D2 receptors linked to adenylate cyclase</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Mottola</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Kilts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Lewis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">S</forename><surname>Connery</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><forename type="middle">D</forename><surname>Walker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Jones</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of Pharmacology and Experimental Therapeutics</title>
		<imprint>
			<biblScope unit="volume">301</biblScope>
			<biblScope unit="page" from="1166" to="1178" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
	<note>PubMed: 12023552</note>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Functional selectivity of dopamine receptor agonists. II. Actions of dihydrexidine in D2L receptor-transfected MN9D cells and pituitary lactotrophs</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Kilts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">S</forename><surname>Connery</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">G</forename><surname>Arrington</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Lewis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">P</forename><surname>Lawler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">S</forename><surname>Oxford</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of Pharmacology and Experimental Therapeutics</title>
		<imprint>
			<biblScope unit="volume">301</biblScope>
			<biblScope unit="page" from="1179" to="1189" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
	<note>PubMed: 12023553</note>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Functional selectivity of D2 receptor ligands in a Chinese hamster ovary hD2L cell line: evidence for induction of ligand-specific receptor states</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Gay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Urban</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Nichols</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">S</forename><surname>Oxford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Mailman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Pharmacol</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="page" from="97" to="105" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
	<note>PubMed: 15213300</note>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Subcutaneous apomorphine in Parkinson&apos;s disease</title>
		<author>
			<persName><forename type="first">W</forename><surname>Poewe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Kleedorfer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Gerstenbrand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Oertel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="page">943</biblScope>
			<date type="published" when="1988">1988</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Continuous subcutaneous apomorphine infusions for fluctuating Parkinson&apos;s disease. Long-term follow-up in 18 patients</title>
		<author>
			<persName><forename type="first">W</forename><surname>Poewe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Kleedorfer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Wagner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bosch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Schelosky</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Adv Neurol</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="page" from="656" to="659" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
	<note>PubMed: 8420206</note>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson&apos;s disease</title>
		<author>
			<persName><forename type="first">A</forename><surname>Colzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Turner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Lees</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurol Neurosurg Psychiatry</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="page" from="573" to="576" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
	<note>PubMed: 9598668</note>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Subcutaneous apomorphine in Parkinson&apos;s disease: response to chronic administration for up to five years</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Hughes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bishop</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Kleedorfer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Turjanski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Fernandez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Lees</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mov Disord</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="165" to="170" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
	<note>PubMed: 8474483</note>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Intranasal apomorphine: a new treatment in Parkinson&apos;s disease [letter]</title>
		<author>
			<persName><forename type="first">R</forename><surname>Kapoor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Turjanski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Frankel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Kleedorfer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Lees</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Stern</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurol Neurosurg Psychiatry</title>
		<imprint>
			<biblScope unit="volume">53</biblScope>
			<biblScope unit="page">1015</biblScope>
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
	<note>PubMed: 2283516</note>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Intranasal apomorphine in parkinsonian on-off fluctuations</title>
		<author>
			<persName><forename type="first">T</forename><surname>Van Laar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">N</forename><surname>Jansen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">W</forename><surname>Essink</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Neef</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Neurol</title>
		<imprint>
			<biblScope unit="volume">49</biblScope>
			<biblScope unit="page" from="482" to="484" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
	<note>PubMed: 1580809</note>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">A new sublingual formulation of apomorphine in the treatment of patients with Parkinson&apos;s disease</title>
		<author>
			<persName><forename type="first">T</forename><surname>Van Laar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Neef</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Danhof</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">I</forename><surname>Roon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Roos</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mov Disord</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="633" to="638" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
	<note>PubMed: 8914088</note>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">The affinities of ergot compounds for dopamine agonist and dopamine antagonist receptor sites</title>
		<author>
			<persName><forename type="first">M</forename><surname>Goldstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">Y</forename><surname>Lew</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sauter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Lieberman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Adv Biochem Psychopharmacol</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page">7395625</biblScope>
			<date type="published" when="1980">1980</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Pergolide: a dopamine agonist at both D 1 and D 2 receptors</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">W</forename><surname>Fuller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Clemens</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Life Sciences</title>
		<imprint>
			<biblScope unit="volume">49</biblScope>
			<biblScope unit="page">1832202</biblScope>
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Dopamine receptor subtypes: beyond the D1/D2 classification</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">H</forename><surname>Andersen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Gingrich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Bates</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Dearry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Falardeau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Senogles</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Trends in Pharmacological Sciences</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="231" to="236" />
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
	<note>PubMed: 2200181</note>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">The D-1 dopamine receptor partial agonist, CY 208-243, exhibits antiparkinsonian activity in the MPTP-treated marmoset</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Temlett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">N</forename><surname>Chong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">H</forename><surname>Oertel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Jenner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">D</forename><surname>Marsden</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">European Journal of Pharmacology</title>
		<imprint>
			<biblScope unit="volume">156</biblScope>
			<biblScope unit="page" from="197" to="206" />
			<date type="published" when="1988">1988</date>
		</imprint>
	</monogr>
	<note>PubMed: 2977118</note>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">The effects of D1 and D2 dopamine receptor agonist and antagonist on parkinsonism in chronic MPTP-treated monkeys</title>
		<author>
			<persName><forename type="first">M</forename><surname>Nomoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Fukuda</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Adv Neurol</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="page" from="119" to="122" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
	<note>PubMed: 8093574</note>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Effect of adding the D1 agonist CY 208-243 to chronic bromocriptine treatment. I: Evaluation of motor parameters in relation to striatal catecholamine content and dopamine receptors</title>
		<author>
			<persName><forename type="first">B</forename><surname>Gomez-Mancilla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Boucher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Gagnon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Di</forename><surname>Paolo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Markstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Bedard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mov Disord</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page">8474480</biblScope>
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">A double-blind, placebo-controlled, dose-ranging study to investigate the safety and efficacy of CY 208-243 in patients with Parkinson&apos;s disease</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Tsui</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">C</forename><surname>Wolters</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">F</forename><surname>Peppard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">B</forename><surname>Calne</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page" from="856" to="858" />
			<date type="published" when="1989">1989</date>
		</imprint>
	</monogr>
	<note>PubMed: 2725884</note>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Serotonin receptors and heart valve disease--it was meant 2B</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Hutcheson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Setola</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">L</forename><surname>Roth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">D</forename><surname>Merryman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacol Ther</title>
		<imprint>
			<biblScope unit="volume">132</biblScope>
			<biblScope unit="page" from="146" to="157" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note>PubMed: 21440001</note>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Studies on renal dopamine receptors with a new agonist</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">G</forename><surname>Pendleton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Samler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Kaiser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">T</forename><surname>Ridley</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">European Journal of Pharmacology</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="page" from="19" to="28" />
			<date type="published" when="1978">1978</date>
		</imprint>
	</monogr>
	<note>PubMed: 29762</note>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">The central effects of a novel dopamine agonist</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">E</forename><surname>Setler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Sarau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Zirkle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">L</forename><surname>Saunders</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">European Journal of Pharmacology</title>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="page" from="419" to="430" />
			<date type="published" when="1978">1978</date>
		</imprint>
	</monogr>
	<note>PubMed: 568069</note>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">Absolute stereochemistry and dopaminergic activity of enantiomers of 2,3,4,5-tetrahydro-7,8-dihydroxy-1phenyl-1H-3-benzazepine</title>
		<author>
			<persName><forename type="first">C</forename><surname>Kaiser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Dandridge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Garvey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Hahn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Sarau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">E</forename><surname>Setler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Med Chem</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="697" to="703" />
			<date type="published" when="1982">1982</date>
		</imprint>
	</monogr>
	<note>PubMed: 6980283</note>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">Dopamine receptors: functions, subtypes and emerging concepts</title>
		<author>
			<persName><forename type="first">C</forename><surname>Kaiser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Jain</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Medicinal Research Reviews-1</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="145" to="229" />
			<date type="published" when="1985">1985</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">Receptor affinities of dopamine D1 receptorselective novel phenylbenzazepines</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Neumeyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">S</forename><surname>Kula</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bergman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Baldessarini</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">European Journal of Pharmacology</title>
		<imprint>
			<biblScope unit="volume">474</biblScope>
			<biblScope unit="page" from="137" to="140" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note>PubMed: 12921854</note>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">Dopamine D1 receptors: efficacy of full (dihydrexidine) vs. partial (SKF38393) agonists in primates vs. rodents</title>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">J</forename><surname>Watts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">P</forename><surname>Lawler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Gilmore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">B</forename><surname>Southerland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Nichols</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Mailman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">European Journal of Pharmacology</title>
		<imprint>
			<biblScope unit="volume">242</biblScope>
			<biblScope unit="page" from="165" to="172" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
	<note>PubMed: 7902811</note>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main">Full&quot; dopamine D1 agonists in human caudate: biochemical properties and therapeutic implications</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Gilmore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">J</forename><surname>Watts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">P</forename><surname>Lawler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">P</forename><surname>Noll</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Nichols</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Mailman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropharmacology</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page">7566481</biblScope>
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">Spare receptors and intrinsic activity: studies with D1 dopamine receptor agonists</title>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">J</forename><surname>Watts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">P</forename><surname>Lawler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Gonzales</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><forename type="middle">Y</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Civelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Nichols</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Synapse</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="177" to="187" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
	<note>PubMed: 8584979</note>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main">A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D(1) agonist, is safe and tolerated in patients with schizophrenia</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>George</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Molnar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">L</forename><surname>Grenesko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Anderson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Mu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Johnson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Schizophrenia Research</title>
		<imprint>
			<biblScope unit="volume">93</biblScope>
			<biblScope unit="page" from="42" to="50" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
	<note>PubMed: 17467956</note>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main">Grooming and vacuous chewing induced by SK&amp;F 83959, an agonist of dopamine &apos;D1-like&apos; receptors that inhibits dopamine-sensitive adenylyl cyclase</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">P</forename><surname>Downes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Waddington</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">European Journal of Pharmacology</title>
		<imprint>
			<biblScope unit="volume">234</biblScope>
			<biblScope unit="page" from="135" to="136" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
	<note>PubMed: 8097163</note>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<title level="a" type="main">Differential antiparkinsonian effects of benzazepine D 1 dopamine agonists with varying efficacies in the MPTPtreated common marmoset</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">K</forename><surname>Gnanalingham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">D</forename><surname>Erol</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Hunter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Jenner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">D</forename><surname>Marsden</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychopharmacology (Berlin)</title>
		<imprint>
			<biblScope unit="volume">117</biblScope>
			<biblScope unit="page" from="275" to="286" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
	<note>PubMed: 7770603</note>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title level="a" type="main">The differential behavioural effects of benzazepine D1 dopamine agonists with varying efficacies, co-administered with quinpirole in primate and rodent models of Parkinson&apos;s disease</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">K</forename><surname>Gnanalingham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Hunter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Jenner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">D</forename><surname>Marsden</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychopharmacology</title>
		<imprint>
			<biblScope unit="volume">117</biblScope>
			<biblScope unit="page" from="287" to="297" />
			<date type="published" when="1995">1995</date>
			<pubPlace>Berlin</pubPlace>
		</imprint>
	</monogr>
	<note>PubMed: 7770604</note>
</biblStruct>

<biblStruct xml:id="b61">
	<analytic>
		<title level="a" type="main">Regulation of c-fos expression by the dopamine D1-D2 receptor heteromer</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Perreault</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">Y</forename><surname>Shen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Fan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>George</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuroscience</title>
		<imprint>
			<biblScope unit="volume">285</biblScope>
			<biblScope unit="page" from="194" to="203" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>PubMed: 25446350</note>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main">SKF-83959 is not a highly-biased functionally selective D1 dopamine receptor ligand with activity at phospholipase C</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kant</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Blake</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Murthy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Boyd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Wyrick</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropharmacology</title>
		<imprint>
			<biblScope unit="volume">86</biblScope>
			<biblScope unit="page" from="145" to="154" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note>PubMed: 24929112</note>
</biblStruct>

<biblStruct xml:id="b63">
	<analytic>
		<title level="a" type="main">Dopamine D1 Receptor Signaling: Does GalphaQ-Phospholipase C Actually Play a Role?</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Mailman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">The Journal of pharmacology and experimental therapeutics</title>
		<imprint>
			<biblScope unit="volume">351</biblScope>
			<biblScope unit="page" from="9" to="17" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note>PubMed: 25052835</note>
</biblStruct>

<biblStruct xml:id="b64">
	<analytic>
		<title level="a" type="main">Evidence against dopamine D1/D2 receptor heteromers</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Frederick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Yano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Trifilieff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">D</forename><surname>Vishwasrao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Biezonski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Meszaros</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Psychiatry</title>
		<imprint>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b65">
	<analytic>
		<title level="a" type="main">Parkinson&apos;s disease and D1 dopamine receptors</title>
		<author>
			<persName><forename type="first">R</forename><surname>Mailman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Nichols</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Current Opinion in Investigational Drugs</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="1582" to="1591" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
	<note>PubMed: 11763161</note>
</biblStruct>

<biblStruct xml:id="b66">
	<analytic>
		<title level="a" type="main">Seizure promotion by D1 agonists does not correlate with other dopaminergic properties</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Starr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">S</forename><surname>Starr</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neural Transm Park Dis Dement Sect</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="27" to="34" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
	<note>PubMed: 8105796</note>
</biblStruct>

<biblStruct xml:id="b67">
	<analytic>
		<title level="a" type="main">Effects of modifications of the 4-(3,4dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinoline structure on dopamine sensitive rat retinal adenylate cyclase activity</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">L</forename><surname>Truex</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Foreman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Riggs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Nichols</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Society for Neuroscience Abstracts</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page">315</biblScope>
			<date type="published" when="1985">1985</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b68">
	<analytic>
		<title level="a" type="main">Thienopyridine derivatives identified as the first selective, full efficacy, dopamine D1 receptor agonists</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">H</forename><surname>Andersen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">B</forename><surname>Nielsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Scheel-Kruger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Jansen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hohlweg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">European Journal of Pharmacology</title>
		<imprint>
			<biblScope unit="volume">137</biblScope>
			<biblScope unit="page" from="291" to="292" />
			<date type="published" when="1987">1987</date>
		</imprint>
	</monogr>
	<note>PubMed: 2956116</note>
</biblStruct>

<biblStruct xml:id="b69">
	<analytic>
		<title level="a" type="main">Dihydrexidine, a novel selective high potency full dopamine D-1 receptor agonist</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">W</forename><surname>Lovenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Brewster</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Mottola</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Riggs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Nichols</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Pharmacol</title>
		<imprint>
			<biblScope unit="volume">166</biblScope>
			<biblScope unit="page" from="111" to="113" />
			<date type="published" when="1989">1989</date>
		</imprint>
	</monogr>
	<note>PubMed: 2572425</note>
</biblStruct>

<biblStruct xml:id="b70">
	<analytic>
		<title level="a" type="main">D1 dopamine receptors of NS20Y neuroblastoma cells are functionally similar to rat striatal D1 receptors</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">W</forename><surname>Lovenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">H</forename><surname>Roth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Nichols</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Mailman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of Neurochemistry</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="page" from="1563" to="1569" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
	<note>PubMed: 1717649</note>
</biblStruct>

<biblStruct xml:id="b71">
	<analytic>
		<title level="a" type="main">Dihydrexidine, a novel full efficacy D 1 dopamine receptor agonist</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Mottola</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Brewster</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">L</forename><surname>Cook</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Nichols</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Mailman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of Pharmacology and Experimental Therapeutics</title>
		<imprint>
			<biblScope unit="volume">262</biblScope>
			<biblScope unit="page" from="383" to="393" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
	<note>PubMed: 1352553</note>
</biblStruct>

<biblStruct xml:id="b72">
	<analytic>
		<title level="a" type="main">b-hexahydrobenzo[a]phenanthridine: A highly potent selective dopamine D1 full agonist</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Brewster</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Nichols</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Riggs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Mottola</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">W</forename><surname>Lovenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Lewis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Med Chem</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page">1756</biblScope>
			<date type="published" when="1990">. trans-10,11-Dihydroxy-5,6,6a,7,8,12. 1990</date>
		</imprint>
	</monogr>
	<note>PubMed: 1971308</note>
</biblStruct>

<biblStruct xml:id="b73">
	<analytic>
		<title level="a" type="main">Dihydrexidine, a full dopamine D1 agonist, reduces MPTP-induced parkinsonism in monkeys</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Taylor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Lawrence</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Redmond</forename><surname>De</surname><genName>Jr</genName></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Elsworth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">H</forename><surname>Roth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Nichols</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">European Journal of Pharmacology</title>
		<imprint>
			<biblScope unit="volume">199</biblScope>
			<biblScope unit="page" from="389" to="391" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
	<note>PubMed: 1680717</note>
</biblStruct>

<biblStruct xml:id="b74">
	<analytic>
		<title level="a" type="main">Dopamine D1 receptor mechanisms in the cognitive performance of young adult and aged monkeys</title>
		<author>
			<persName><forename type="first">Aft</forename><surname>Arnsten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">X</forename><surname>Cai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">L</forename><surname>Murphy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">S</forename><surname>Goldman-Rakic</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychopharmacology</title>
		<imprint>
			<biblScope unit="volume">116</biblScope>
			<biblScope unit="page" from="143" to="151" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
	<note>PubMed: 7862943</note>
</biblStruct>

<biblStruct xml:id="b75">
	<analytic>
		<title level="a" type="main">Behavioral effects in the rat of dihydrexidine, a high-potency, full-efficacy D1 dopamine receptor agonist</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Darney</surname><genName>Jr</genName></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Lewis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Brewster</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Nichols</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Mailman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropsychopharmacology</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="187" to="195" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
	<note>PubMed: 1684499</note>
</biblStruct>

<biblStruct xml:id="b76">
	<analytic>
		<title level="a" type="main">A68930: a potent and specific agonist for the D-1 dopamine receptor</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Kebabian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Briggs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Britton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Asin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Deninno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">G</forename><surname>Mackenzie</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">American Journal of Hypertension</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="40S" to="42" />
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
	<note>PubMed: 2143387</note>
</biblStruct>

<biblStruct xml:id="b77">
	<analytic>
		<title level="a" type="main">A-77636: a potent and selective dopamine D1 receptor agonist with antiparkinsonian activity in marmosets</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Kebabian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Britton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Deninno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Perner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Jenner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Pharmacol</title>
		<imprint>
			<biblScope unit="volume">229</biblScope>
			<biblScope unit="page" from="203" to="209" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
	<note>PubMed: 1362704</note>
</biblStruct>

<biblStruct xml:id="b78">
	<analytic>
		<title level="a" type="main">A68930: a potent agonist selective for the dopamine D1 receptor</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Deninno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Schoenleber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Mackenzie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Britton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">E</forename><surname>Asin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Briggs</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">European Journal of Pharmacology</title>
		<imprint>
			<biblScope unit="volume">199</biblScope>
			<biblScope unit="page" from="209" to="219" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
	<note>PubMed: 1683288</note>
</biblStruct>

<biblStruct xml:id="b79">
	<analytic>
		<title level="a" type="main">Differential effect of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6tetrahydropyridine-exposed monkeys</title>
		<author>
			<persName><forename type="first">P</forename><surname>Blanchet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Bedard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Britton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Kebabian</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of Pharmacology and Experimental Therapeutics</title>
		<imprint>
			<biblScope unit="volume">267</biblScope>
			<biblScope unit="page" from="275" to="279" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
	<note>PubMed: 7901395</note>
</biblStruct>

<biblStruct xml:id="b80">
	<analytic>
		<title level="a" type="main">Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus)</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">K</forename><surname>Pearce</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jackson</forename><forename type="middle">M</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Jenner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Marsden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">D</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mov Disord</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="731" to="740" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
	<note>PubMed: 8749992</note>
</biblStruct>

<biblStruct xml:id="b81">
	<analytic>
		<title level="a" type="main">Effects of repeated dopamine D 1 receptor stimulation on rotation and cfos expression</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">E</forename><surname>Asin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Wirtshafter</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">European Journal of Pharmacology</title>
		<imprint>
			<biblScope unit="volume">235</biblScope>
			<biblScope unit="page" from="167" to="168" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
	<note>PubMed: 8100194</note>
</biblStruct>

<biblStruct xml:id="b82">
	<analytic>
		<title level="a" type="main">Rapid reversal of denervation supersensitivity of dopamine D1 receptors by l-dopa or a novel dopamine D1 receptor agonist, A68930</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Britton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Kebabian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Curzon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">European Journal of Pharmacology</title>
		<imprint>
			<biblScope unit="volume">200</biblScope>
			<biblScope unit="page" from="89" to="93" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
	<note>PubMed: 1685124</note>
</biblStruct>

<biblStruct xml:id="b83">
	<analytic>
		<title level="a" type="main">Dopamine D 1 receptor desensitization profile in MPTP-lesioned primates</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Blanchet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Grondin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Bedard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Shiosaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Britton</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">European Journal of Pharmacology</title>
		<imprint>
			<biblScope unit="volume">309</biblScope>
			<biblScope unit="page" from="13" to="20" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
	<note>PubMed: 8864687</note>
</biblStruct>

<biblStruct xml:id="b84">
	<analytic>
		<title level="a" type="main">-diol (A-86929) a potent and selective dopamine D1 agonist that maintains behavioral efficacy following repeated administration and characterization of its diacetyl prodrug (ABT-431)</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Michaelides</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Hong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Didomenico</surname></persName>
		</author>
		<author>
			<persName><surname>Jr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">E</forename><surname>Asin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Britton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Lin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of Medicinal Chemistry</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="3445" to="3447" />
			<date type="published" when="1995">5aR, 11bS)-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-azacyclopent-1-ena[c]-phenanthrene-9,10. 1995</date>
		</imprint>
	</monogr>
	<note>PubMed: 7658429</note>
</biblStruct>

<biblStruct xml:id="b85">
	<analytic>
		<title level="a" type="main">ABT-431: the diacetyl prodrug of A-86929, a potent and selective dopamine D 1 receptor agonist: in vitro characterization and effects in animal models of Parkinson&apos;s disease</title>
		<author>
			<persName><forename type="first">K</forename><surname>Shiosaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Jenner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">E</forename><surname>Asin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Britton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Michaelides</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of Pharmacology and Experimental Therapeutics</title>
		<imprint>
			<biblScope unit="volume">276</biblScope>
			<biblScope unit="page" from="150" to="160" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
	<note>PubMed: 8558425</note>
</biblStruct>

<biblStruct xml:id="b86">
	<analytic>
		<title level="a" type="main">ABT-431, a D1 receptor agonist prodrug, has efficacy in Parkinson&apos;s disease</title>
		<author>
			<persName><forename type="first">O</forename><surname>Rascol</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Blin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Thalamas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Descombes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Soubrouillard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Azulay</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Annals of Neurology</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="736" to="741" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
	<note>PubMed: 10360765</note>
</biblStruct>

<biblStruct xml:id="b87">
	<analytic>
		<title level="a" type="main">9-Dihydroxy-2,3,7,11b-tetrahydro-1Hnaph[1,2,3-de]isoquinoline: a potent full dopamine D1 agonist containing a rigid-betaphenyldopamine pharmacophore</title>
		<author>
			<persName><forename type="first">D</forename><surname>Ghosh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Snyder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">J</forename><surname>Watts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Mailman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Nichols</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of Medicinal Chemistry</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page" from="549" to="555" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
	<note>PubMed: 8558526</note>
</biblStruct>

<biblStruct xml:id="b88">
	<analytic>
		<title level="a" type="main">Dinapsoline: characterization of a D 1 dopamine receptor agonist in a rat model of Parkinson&apos;s disease</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Gulwadi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">D</forename><surname>Korpinen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Mailman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Nichols</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">Y</forename><surname>Sit</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Taber</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of Pharmacology and Experimental Therapeutics</title>
		<imprint>
			<biblScope unit="volume">296</biblScope>
			<biblScope unit="page" from="338" to="344" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
	<note>PubMed: 11160615</note>
</biblStruct>

<biblStruct xml:id="b89">
	<analytic>
		<title level="a" type="main">Homologous desensitization of the D1A dopamine receptor: efficacy in causing desensitization dissociates from both receptor occupancy and functional potency</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Lewis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">J</forename><surname>Watts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">P</forename><surname>Lawler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Nichols</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Mailman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of Pharmacology and Experimental Therapeutics</title>
		<imprint>
			<biblScope unit="volume">286</biblScope>
			<biblScope unit="page" from="345" to="353" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
	<note>PubMed: 9655879</note>
</biblStruct>

<biblStruct xml:id="b90">
	<analytic>
		<title level="a" type="main">Functional selectivity of dopamine D(1) receptor agonists in regulating the fate of internalized receptors</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Ryman-Rasmussen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Griffith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Oloff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Vaidehi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Brown</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Goddard</forename><forename type="middle">Wa</forename><surname>Iii</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropharmacology</title>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="page" from="562" to="575" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
	<note>PubMed: 17067639</note>
</biblStruct>

<biblStruct xml:id="b91">
	<analytic>
		<title level="a" type="main">Effects of the full dopamine D1 receptor agonist dihydrexidine in Parkinson&apos;s disease</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Blanchet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Fang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gillespie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Sabounjian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">W</forename><surname>Locke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Gammans</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clinical Neuropharmacology</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="339" to="343" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
	<note>PubMed: 9844789</note>
</biblStruct>

<biblStruct xml:id="b92">
	<analytic>
		<title level="a" type="main">Pharmacological characterisation and autoradiographic localisation of dopamine receptor subtypes in the cardiovascular system and in the kidney</title>
		<author>
			<persName><forename type="first">F</forename><surname>Amenta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Ferrante</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ricci</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hypertens Res</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="issue">Suppl 1</biblScope>
			<biblScope unit="page" from="23" to="S27" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
	<note>PubMed: 8529069</note>
</biblStruct>

<biblStruct xml:id="b93">
	<analytic>
		<title level="a" type="main">A single 20 mg dose of the full D(1) dopamine agonist dihydrexidine (DAR-0100) increases prefrontal perfusion in schizophrenia</title>
		<author>
			<persName><forename type="first">Q</forename><surname>Mu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">S</forename><surname>Morgan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">L</forename><surname>Grenesko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Molnar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Anderson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Schizophrenia Research</title>
		<imprint>
			<biblScope unit="volume">94</biblScope>
			<biblScope unit="page" from="332" to="341" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
	<note>PubMed: 17596915</note>
</biblStruct>

<biblStruct xml:id="b94">
	<analytic>
		<title level="a" type="main">Effects of the D1 dopamine receptor agonist dihydrexidine (DAR-0100A) on working memory in schizotypal personality disorder</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Rosell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">C</forename><surname>Zaluda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Mcclure</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Perez-Rodriguez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">S</forename><surname>Strike</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Barch</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropsychopharmacology</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="446" to="453" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>PubMed: 25074637</note>
</biblStruct>

<biblStruct xml:id="b95">
	<analytic>
		<title level="a" type="main">Persistent activation of the dopamine D 1 receptor contributes to prolonged receptor desensitization: studies with A-77636</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">R</forename><surname>Bianchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">R</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Stashko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Curzon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of Pharmacology and Experimental Therapeutics</title>
		<imprint>
			<biblScope unit="volume">276</biblScope>
			<biblScope unit="page" from="1022" to="1029" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
	<note>PubMed: 8786531</note>
</biblStruct>

<biblStruct xml:id="b96">
	<analytic>
		<title level="a" type="main">Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs</title>
		<author>
			<persName><forename type="first">I</forename><surname>Creese</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Burt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Snyder</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">192</biblScope>
			<biblScope unit="page" from="481" to="483" />
			<date type="published" when="1976">1976</date>
		</imprint>
	</monogr>
	<note>PubMed: 3854</note>
</biblStruct>

<biblStruct xml:id="b97">
	<analytic>
		<title level="a" type="main">The history of the psychopharmacology of schizophrenia</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">E</forename><surname>Lehmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">A</forename><surname>Ban</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Can J Psychiatry</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="152" to="162" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
	<note>PubMed: 9067064</note>
</biblStruct>

<biblStruct xml:id="b98">
	<analytic>
		<title level="a" type="main">Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs</title>
		<author>
			<persName><forename type="first">S</forename><surname>Miyamoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">E</forename><surname>Duncan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Marx</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Lieberman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Psychiatry</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="79" to="104" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note>PubMed: 15289815</note>
</biblStruct>

<biblStruct xml:id="b99">
	<analytic>
		<title level="a" type="main">Provocative tests with psychostimulant drugs in schizophrenia</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Lieberman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Kane</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Alvir</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychopharmacology (Berl)</title>
		<imprint>
			<biblScope unit="volume">91</biblScope>
			<biblScope unit="page" from="415" to="433" />
			<date type="published" when="1987">1987</date>
		</imprint>
	</monogr>
	<note>PubMed: 2884687</note>
</biblStruct>

<biblStruct xml:id="b100">
	<analytic>
		<title level="a" type="main">Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drugfree schizophrenic subjects</title>
		<author>
			<persName><forename type="first">M</forename><surname>Laruelle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Abi-Dargham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Van Dyck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Gil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D'</forename><surname>Souza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">D</forename><surname>Erdos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci</title>
		<imprint>
			<biblScope unit="volume">93</biblScope>
			<biblScope unit="page" from="9235" to="9240" />
			<date type="published" when="1996">1996</date>
			<pubPlace>U S A.</pubPlace>
		</imprint>
	</monogr>
	<note>PubMed: 8799184</note>
</biblStruct>

<biblStruct xml:id="b101">
	<analytic>
		<title level="a" type="main">Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort</title>
		<author>
			<persName><forename type="first">A</forename><surname>Abi-Dargham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Gil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Krystal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Baldwin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Seibyl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bowers</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Psychiatry</title>
		<imprint>
			<biblScope unit="volume">155</biblScope>
			<biblScope unit="page" from="761" to="767" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
	<note>PubMed: 9619147</note>
</biblStruct>

<biblStruct xml:id="b102">
	<analytic>
		<title level="a" type="main">Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method</title>
		<author>
			<persName><forename type="first">A</forename><surname>Breier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">P</forename><surname>Su</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Saunders</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Carson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">S</forename><surname>Kolachana</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>De Bartolomeis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci U S A</title>
		<imprint>
			<biblScope unit="volume">94</biblScope>
			<biblScope unit="page" from="2569" to="2574" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
	<note>PubMed: 9122236</note>
</biblStruct>

<biblStruct xml:id="b103">
	<analytic>
		<title level="a" type="main">Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients</title>
		<author>
			<persName><forename type="first">J</forename><surname>Hietala</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Syvalahti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Vuorio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Rakkolainen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bergman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Haaparanta</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">346</biblScope>
			<biblScope unit="page" from="1130" to="1131" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
	<note>PubMed: 7475604</note>
</biblStruct>

<biblStruct xml:id="b104">
	<analytic>
		<title level="a" type="main">Presynaptic dopaminergic dysfunction in schizophrenia -A positron emission tomographic [F-18]fluorodopa study</title>
		<author>
			<persName><forename type="first">S</forename><surname>Mcgowan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Lawrence</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Sales</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Quested</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Grasby</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Gen Psychiat</title>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="page" from="134" to="142" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
	<note>PubMed: 14757589</note>
</biblStruct>

<biblStruct xml:id="b105">
	<analytic>
		<title level="a" type="main">Elevated Dopa Decarboxylase Activity in Living Brain of Patients with Psychosis</title>
		<author>
			<persName><forename type="first">J</forename><surname>Reith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Benkelfat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sherwin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Yasuhara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Kuwabara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Andermann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">P Natl Acad Sci USA</title>
		<imprint>
			<biblScope unit="volume">91</biblScope>
			<biblScope unit="page" from="11651" to="11654" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b106">
	<analytic>
		<title level="a" type="main">Increased baseline occupancy of D2 receptors by dopamine in schizophrenia</title>
		<author>
			<persName><forename type="first">A</forename><surname>Abi-Dargham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Rodenhiser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Printz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Zea</forename><forename type="middle">-</forename><surname>Ponce</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Gil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Kegeles</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">S</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci U S A</title>
		<imprint>
			<biblScope unit="volume">97</biblScope>
			<biblScope unit="page" from="8104" to="8109" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
	<note>PubMed: 10884434</note>
</biblStruct>

<biblStruct xml:id="b107">
	<analytic>
		<title level="a" type="main">Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies</title>
		<author>
			<persName><forename type="first">A</forename><surname>Abi-Dargham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Laruelle</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Psychiatry</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="15" to="27" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note>PubMed: 15642439</note>
</biblStruct>

<biblStruct xml:id="b108">
	<analytic>
		<title level="a" type="main">The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: Combined results of the North American trials</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Marder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Davis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Chouinard</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Psychiat</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page" from="538" to="546" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b109">
	<analytic>
		<title level="a" type="main">Effects of Clozapine on Positive and Negative Symptoms in Outpatients with Schizophrenia</title>
		<author>
			<persName><forename type="first">A</forename><surname>Breier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">W</forename><surname>Buchanan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Kirkpatrick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">R</forename><surname>Davis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Irish</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Summerfelt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Psychiat</title>
		<imprint>
			<biblScope unit="volume">151</biblScope>
			<biblScope unit="page" from="20" to="26" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
	<note>PubMed: 8267129</note>
</biblStruct>

<biblStruct xml:id="b110">
	<analytic>
		<title level="a" type="main">Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia</title>
		<author>
			<persName><forename type="first">S</forename><surname>Kasper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">N</forename><surname>Lerman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">D</forename><surname>Mcquade</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Saha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">H</forename><surname>Carson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ali</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Neuropsychopharmacol</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="325" to="337" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note>PubMed: 14609439</note>
</biblStruct>

<biblStruct xml:id="b111">
	<analytic>
		<title level="a" type="main">Assessing the effects of atypical antipsychotics on negative symptoms</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">Y</forename><surname>Meltzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Casey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Garver</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Marder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">S</forename><surname>Masand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Miller</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Psychiat</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="page" from="28" to="34" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b112">
	<analytic>
		<title level="a" type="main">Does risperidone improve verbal working memory in treatment-resistant schizophrenia?</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Green</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">D</forename><surname>Marshall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">C</forename><surname>Wirshing</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Ames</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Marder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mcgurk</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Psychiat</title>
		<imprint>
			<biblScope unit="volume">154</biblScope>
			<biblScope unit="page" from="799" to="804" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
	<note>PubMed: 9167507</note>
</biblStruct>

<biblStruct xml:id="b113">
	<analytic>
		<title level="a" type="main">Risperidone vs. haloperidol on reaction time, manual dexterity, and motor learning in treatment-resistant schizophrenia patients</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Kern</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Green</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">D</forename><surname>Marshall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">C</forename><surname>Wirshing</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Wirshing</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mcgurk</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biol Psychiat</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page" from="726" to="732" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
	<note>PubMed: 9798076</note>
</biblStruct>

<biblStruct xml:id="b114">
	<analytic>
		<title level="a" type="main">The neurocognitive effects of low-dose haloperidol: A two-year comparison with risperidone</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Green</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Marder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Glynn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Mcgurk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">C</forename><surname>Wirshing</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Wirshing</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biol Psychiat</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="page" from="972" to="978" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
	<note>PubMed: 12062881</note>
</biblStruct>

<biblStruct xml:id="b115">
	<analytic>
		<title level="a" type="main">Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in firstepisode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Keefe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Seidman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">K</forename><surname>Christensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Hamer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Sharma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Sitskoorn</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Psychiatry</title>
		<imprint>
			<biblScope unit="volume">161</biblScope>
			<biblScope unit="page" from="985" to="995" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
	<note>PubMed: 15169686</note>
</biblStruct>

<biblStruct xml:id="b116">
	<analytic>
		<title level="a" type="main">Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Keefe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Seidman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">K</forename><surname>Christensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Hamer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Sharma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Sitskoorn</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biol Psychiatry</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="page" from="97" to="105" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
	<note>PubMed: 16140282</note>
</biblStruct>

<biblStruct xml:id="b117">
	<analytic>
		<title level="a" type="main">Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Keefe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Bilder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Davis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">D</forename><surname>Harvey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">W</forename><surname>Palmer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Gold</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Gen Psychiatry</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="page" from="633" to="647" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
	<note>PubMed: 17548746</note>
</biblStruct>

<biblStruct xml:id="b118">
	<analytic>
		<title level="a" type="main">Is it possible to be schizophrenic yet neuropsychologically normal?</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">W</forename><surname>Palmer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">K</forename><surname>Heaton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Paulsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kuck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Braff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Harris</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropsychology</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="437" to="446" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
	<note>PubMed: 9223148</note>
</biblStruct>

<biblStruct xml:id="b119">
	<analytic>
		<title level="a" type="main">Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Bilder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Goldman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Robinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Reiter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Bell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Bates</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Psychiatry</title>
		<imprint>
			<biblScope unit="volume">157</biblScope>
			<biblScope unit="page" from="549" to="559" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
	<note>PubMed: 10739413</note>
</biblStruct>

<biblStruct xml:id="b120">
	<analytic>
		<title level="a" type="main">Developmental Processes in Schizophrenic Disorders: longitudinal studies of vulnerability and stress</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">H</forename><surname>Nuechterlein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Dawson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gitlin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Ventura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Goldstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">S</forename><surname>Snyder</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Schizophr Bull</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="387" to="425" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
	<note>PubMed: 1411329</note>
</biblStruct>

<biblStruct xml:id="b121">
	<analytic>
		<title level="a" type="main">What are the functional consequences of neurocognitive deficits in schizophrenia?</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Green</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Psychiatry</title>
		<imprint>
			<biblScope unit="volume">153</biblScope>
			<biblScope unit="page" from="321" to="330" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
	<note>PubMed: 8610818</note>
</biblStruct>

<biblStruct xml:id="b122">
	<analytic>
		<title level="a" type="main">Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the &quot;right stuff</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Green</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Kern</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Braff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Mintz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Schizophr Bull</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="119" to="136" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
	<note>PubMed: 10755673</note>
</biblStruct>

<biblStruct xml:id="b123">
	<analytic>
		<title level="a" type="main">Effect of lesion of cortical dopamine terminals on subcortical dopamine receptors in rats</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Pycock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">W</forename><surname>Kerwin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Carter</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">286</biblScope>
			<biblScope unit="page">7393327</biblScope>
			<date type="published" when="1980">1980</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b124">
	<analytic>
		<title level="a" type="main">Implications of normal brain development for the pathogenesis of schizophrenia</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Weinberger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Gen Psychiatry</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page" from="660" to="669" />
			<date type="published" when="1987">1987</date>
		</imprint>
	</monogr>
	<note>PubMed: 3606332</note>
</biblStruct>

<biblStruct xml:id="b125">
	<analytic>
		<title level="a" type="main">Dopamine in schizophrenia: a review and reconceptualization</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">L</forename><surname>Davis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Kahn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Ko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Davidson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Psychiatry</title>
		<imprint>
			<biblScope unit="volume">148</biblScope>
			<biblScope unit="page" from="1474" to="1486" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
	<note>PubMed: 1681750</note>
</biblStruct>

<biblStruct xml:id="b126">
	<analytic>
		<title level="a" type="main">D1 dopamine receptors in prefrontal cortex: Involvement in working memory</title>
		<author>
			<persName><forename type="first">T</forename><surname>Sawaguchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">S</forename><surname>Goldman-Rakic</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">251</biblScope>
			<biblScope unit="page" from="947" to="950" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
	<note>PubMed: 1825731</note>
</biblStruct>

<biblStruct xml:id="b127">
	<analytic>
		<title level="a" type="main">The role of D1-dopamine receptor in working memory: local injections of dopamine antagonists into the prefrontal cortex of rhesus monkeys performing an oculomotor delayed-response task</title>
		<author>
			<persName><forename type="first">T</forename><surname>Sawaguchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">S</forename><surname>Goldman-Rakic</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurophysiol</title>
		<imprint>
			<biblScope unit="volume">71</biblScope>
			<biblScope unit="page" from="515" to="528" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
	<note>PubMed: 7909839</note>
</biblStruct>

<biblStruct xml:id="b128">
	<analytic>
		<title level="a" type="main">D1 receptor modulation of hippocampal-prefrontal cortical circuits integrating spatial memory with executive functions in the rat</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Seamans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">B</forename><surname>Floresco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Phillips</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">The Journal of neuroscience: the official journal of the Society for Neuroscience</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="1613" to="1621" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
	<note>PubMed: 9454866</note>
</biblStruct>

<biblStruct xml:id="b129">
	<analytic>
		<title level="a" type="main">Supranormal stimulation of dopamine D1 receptors in the rodent prefrontal cortex impairs spatial working memory performance</title>
		<author>
			<persName><forename type="first">J</forename><surname>Zahrt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Taylor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">G</forename><surname>Mathew</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Aft</forename><surname>Arnsten</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurosci</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="8528" to="8535" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
	<note>PubMed: 9334425</note>
</biblStruct>

<biblStruct xml:id="b130">
	<analytic>
		<title level="a" type="main">Catecholamine regulation of the prefrontal cortex</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">F</forename><surname>Arnsten</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Psychopharmacol</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="151" to="162" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
	<note>PubMed: 9208378</note>
</biblStruct>

<biblStruct xml:id="b131">
	<analytic>
		<title level="a" type="main">Prefrontal DA transmission at D1 receptors and the pathology of schizophrenia</title>
		<author>
			<persName><forename type="first">A</forename><surname>Abi-Dargham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Moore</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuroscientist</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="404" to="416" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note>PubMed: 14580124</note>
</biblStruct>

<biblStruct xml:id="b132">
	<analytic>
		<title level="a" type="main">Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in working memory</title>
		<author>
			<persName><forename type="first">S</forename><surname>Vijayraghavan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">G</forename><surname>Birnbaum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Bruce</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">V</forename><surname>Williams</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Aft</forename><surname>Arnsten</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature Neuroscience</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="376" to="384" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
	<note>PubMed: 17277774</note>
</biblStruct>

<biblStruct xml:id="b133">
	<analytic>
		<title level="a" type="main">Mesocortical dopaminergic function and human cognition</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Weinberger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">F</forename><surname>Berman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">N</forename><surname>Chase</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann N Y Acad Sci</title>
		<imprint>
			<biblScope unit="volume">537</biblScope>
			<biblScope unit="page" from="330" to="338" />
			<date type="published" when="1988">1988</date>
		</imprint>
	</monogr>
	<note>PubMed: 2974264</note>
</biblStruct>

<biblStruct xml:id="b134">
	<analytic>
		<title level="a" type="main">Neuropsychological correlates of central monoamine function in chronic schizophrenia: relationship between CSF metabolites and cognitive function</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Kahn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">D</forename><surname>Harvey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Davidson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Keefe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Apter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Neale</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Schizophr Res</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="217" to="224" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
	<note>PubMed: 7514887</note>
</biblStruct>

<biblStruct xml:id="b135">
	<analytic>
		<title level="a" type="main">The effect of amphetamine on regional cerebral blood flow during cognitive activation in schizophrenia</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Daniel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Weinberger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename><surname>Jones</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Zigun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Coppola</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Handel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">The Journal of neuroscience: the official journal of the Society for Neuroscience</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="1907" to="1917" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
	<note>PubMed: 2066768</note>
</biblStruct>

<biblStruct xml:id="b136">
	<analytic>
		<title level="a" type="main">Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Egan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">E</forename><surname>Goldberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">S</forename><surname>Kolachana</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Callicott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Mazzanti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Straub</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci U S A</title>
		<imprint>
			<biblScope unit="volume">98</biblScope>
			<biblScope unit="page" from="6917" to="6922" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
	<note>PubMed: 11381111</note>
</biblStruct>

<biblStruct xml:id="b137">
	<analytic>
		<title level="a" type="main">Lamina-specific alterations in the dopamine innervation of the prefrontal cortex in schizophrenic subjects</title>
		<author>
			<persName><forename type="first">M</forename><surname>Akil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">N</forename><surname>Pierri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Whitehead</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Edgar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Mohila</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Sampson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Psychiatry</title>
		<imprint>
			<biblScope unit="volume">156</biblScope>
			<biblScope unit="page" from="1580" to="1589" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
	<note>PubMed: 10518170</note>
</biblStruct>

<biblStruct xml:id="b138">
	<analytic>
		<title level="a" type="main">A postmortem study of frontal cortical dopamine D1 receptors in schizophrenics, psychiatric controls, and normal controls</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">B</forename><surname>Knable</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">M</forename><surname>Hyde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Murray</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Herman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Kleinman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biol Psychiatry</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="1191" to="1199" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
	<note>PubMed: 8959283</note>
</biblStruct>

<biblStruct xml:id="b139">
	<analytic>
		<title level="a" type="main">Dopamine receptor transcript expression in striatum and prefrontal and occipital cortex. Focal abnormalities in orbitofrontal cortex in schizophrenia</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Meador-Woodruff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Haroutunian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Powchik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Davidson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">L</forename><surname>Davis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Watson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Gen Psychiatry</title>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="page" from="1089" to="1095" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
	<note>PubMed: 9400344</note>
</biblStruct>

<biblStruct xml:id="b140">
	<analytic>
		<title level="a" type="main">Increased prefrontal cortical D1 receptors in drug naive patients with schizophrenia: a PET study with [11C]NNC112</title>
		<author>
			<persName><forename type="first">A</forename><surname>Abi-Dargham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Thompson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Gil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">S</forename><surname>Kegeles</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">B</forename><surname>Urban</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Psychopharmacol</title>
		<imprint>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b141">
	<analytic>
		<title level="a" type="main">Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Okubo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Suhara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Suzuki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kobayashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Inoue</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Terasaki</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">385</biblScope>
			<biblScope unit="page" from="634" to="636" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
	<note>PubMed: 9024661</note>
</biblStruct>

<biblStruct xml:id="b142">
	<analytic>
		<title level="a" type="main">PET study of D(1) dopamine receptor binding in neuroleptic-naive patients with schizophrenia</title>
		<author>
			<persName><forename type="first">P</forename><surname>Karlsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Farde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Halldin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Sedvall</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Psychiatry</title>
		<imprint>
			<biblScope unit="volume">159</biblScope>
			<biblScope unit="page" from="761" to="767" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
	<note>PubMed: 11986129</note>
</biblStruct>

<biblStruct xml:id="b143">
	<analytic>
		<title level="a" type="main">Deficits in prefrontal cortical and extra-striatal dopamine release in schizophrenia: a PET fMRI study</title>
		<author>
			<persName><forename type="first">M</forename><surname>Slifstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Van De Giessen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Van</forename><surname>Snellenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">X</forename><surname>Thompson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Narendran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Gil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAMA Psychiatry</title>
		<imprint>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b144">
	<analytic>
		<title level="a" type="main">Pergolide treatment of cognitive deficits associated with schizotypal personality disorder: continued evidence of the importance of the dopamine system in the schizophrenia spectrum</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Mcclure</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">D</forename><surname>Harvey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Goodman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Triebwasser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>New</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">W</forename><surname>Koenigsberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropsychopharmacology</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="1356" to="1362" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note>PubMed: 20130535</note>
</biblStruct>

<biblStruct xml:id="b145">
	<analytic>
		<title level="a" type="main">Dopaminergic benzo[a]phenanthridines: resolution and pharmacological evaluation of the enantiomers of dihydrexidine, the full efficacy D1 dopamine receptor agonist</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">A</forename><surname>Knoerzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Nichols</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Brewster</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">J</forename><surname>Watts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Mottola</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Mailman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Med Chem</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="2453" to="2460" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
	<note>PubMed: 7914538</note>
</biblStruct>

<biblStruct xml:id="b146">
	<analytic>
		<title level="a" type="main">Characterization of in vivo pharmacokinetic properties of the dopamine D1 receptor agonist DAR-0100A in nonhuman primates using PET with [11C] NNC112 and [11C] raclopride</title>
		<author>
			<persName><forename type="first">M</forename><surname>Slifstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">F</forename><surname>Suckow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Javitch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Cooper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lieberman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Abi-Dargham</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cereb Blood Flow Metab</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="293" to="304" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note>PubMed: 20571519</note>
</biblStruct>

<biblStruct xml:id="b147">
	<analytic>
		<title level="a" type="main">Discovery of D1 Dopamine Receptor Positive Allosteric Modulators (PAM) Characterization of Pharmacology and Identification of Residues Which Regulate Species Selectivity</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Lewis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Hunihan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Watson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">G</forename><surname>Gentles</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Huang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of Pharmacology and Experimental Therapeutics</title>
		<imprint>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b148">
	<monogr>
		<title level="m" type="main">WPO. 3,4-dihydroisoquinolin-2(1h)-yl compounds</title>
		<author>
			<persName><forename type="first">Dbcda</forename><surname>Beadle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Hao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Jr; Krushinski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Reinhard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Schaus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">D</forename><surname>Wolfangel</surname></persName>
		</author>
		<ptr target="https://wwwgooglecom/patents/WO2014193781A1?cl=en" />
		<imprint>
			<date type="published" when="2014">2014</date>
			<publisher>Lilly Inc</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b149">
	<analytic>
		<title level="a" type="main">Partial and full dopamine D1 agonists produce comparable increases in ventral pallidal neuronal activity: contribution of endogenous dopamine</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Heidenreich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Mailman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Nichols</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">C</forename><surname>Napier</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">The Journal of pharmacology and experimental therapeutics</title>
		<imprint>
			<biblScope unit="volume">273</biblScope>
			<biblScope unit="page">7714807</biblScope>
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
